<SEC-DOCUMENT>0001437749-24-020277.txt : 20240614
<SEC-HEADER>0001437749-24-020277.hdr.sgml : 20240614
<ACCEPTANCE-DATETIME>20240614084755
ACCESSION NUMBER:		0001437749-24-020277
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		17
CONFORMED PERIOD OF REPORT:	20240614
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240614
DATE AS OF CHANGE:		20240614

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NovaBay Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001389545
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				680454536
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33678
		FILM NUMBER:		241043245

	BUSINESS ADDRESS:	
		STREET 1:		2000 POWELL STREET, SUITE 1150
		CITY:			EMERYVILLE
		STATE:			CA
		ZIP:			94608
		BUSINESS PHONE:		(510) 899-8800

	MAIL ADDRESS:	
		STREET 1:		2000 POWELL STREET, SUITE 1150
		CITY:			EMERYVILLE
		STATE:			CA
		ZIP:			94608
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>nby20240614_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:naics="http://xbrl.sec.gov/naics/2023" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:utreg="http://www.xbrl.org/2009/utr" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:us-roles="http://fasb.org/us-roles/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:thunderdome="http://www.RDGFilings.com" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:rr="http://xbrl.sec.gov/rr/2018-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:nby="http://www.nby.com/20240614"><head>
	<title>nby20240614_8k.htm</title>

	<!-- Generated by ThunderDome Portal - 6/14/2024 12:34:24 PM -->
<meta http-equiv="Content-Type" content="text/html"/></head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;"><div style="display: none">
<ix:header>
<ix:hidden>
<ix:nonNumeric contextRef="d20248K" name="dei:AmendmentFlag" id="ixv-345">false</ix:nonNumeric>
<ix:nonNumeric contextRef="d20248K" name="dei:EntityCentralIndexKey" id="ixv-346">0001389545</ix:nonNumeric>

</ix:hidden>
<ix:references>
<link:schemaRef xlink:href="nby-20240614.xsd" xlink:type="simple"/>
</ix:references>
<ix:resources>
<xbrli:context id="d20248K">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001389545</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2024-06-14</xbrli:startDate>
<xbrli:endDate>2024-06-14</xbrli:endDate>
</xbrli:period>
</xbrli:context>



</ix:resources>
</ix:header>
</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>UNITED STATES</b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>SECURITIES AND EXCHANGE COMMISSION</b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>WASHINGTON, D.C. 20549</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>FORM</b>&#160;<ix:nonNumeric contextRef="d20248K" name="dei:DocumentType" id="ixv-17"><b>8-K</b></ix:nonNumeric></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>CURRENT REPORT</b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Pursuant to Section 13 or 15(d) of the</b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Securities Exchange Act of 1934</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Date of earliest event reported:</b>&#160;<ix:nonNumeric contextRef="d20248K" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="ixv-356">June 14, 2024</ix:nonNumeric></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20248K" name="dei:EntityRegistrantName" id="ixv-357">NovaBay Pharmaceuticals, Inc.</ix:nonNumeric></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(Exact Name of Registrant as Specified in Charter)</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:15.4%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20248K" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="ixv-358">Delaware</ix:nonNumeric></div>
			</td>
			<td style="vertical-align:top;width:15.4%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20248K" name="dei:EntityFileNumber" id="ixv-359">001-33678</ix:nonNumeric></div>
			</td>
			<td style="vertical-align:top;width:15.4%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20248K" name="dei:EntityTaxIdentificationNumber" id="ixv-360">68-0454536</ix:nonNumeric></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:15.4%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(State or Other Jurisdiction</b></div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>of Incorporation)</b></div>
			</td>
			<td style="vertical-align:top;width:15.4%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(Commission File Number)</b></div>
			</td>
			<td style="vertical-align:top;width:15.4%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(I.R.S. Employer</b></div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Identification No.)</b></div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20248K" name="dei:EntityAddressAddressLine1" id="ixv-361">2000 Powell Street, Suite 1150</ix:nonNumeric>,&#160;<ix:nonNumeric contextRef="d20248K" name="dei:EntityAddressCityOrTown" id="ixv-362">Emeryville</ix:nonNumeric>,&#160;<ix:nonNumeric contextRef="d20248K" name="dei:EntityAddressStateOrProvince" id="ixv-363">CA</ix:nonNumeric>&#160;<ix:nonNumeric contextRef="d20248K" name="dei:EntityAddressPostalZipCode" id="ixv-364">94608</ix:nonNumeric></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(Address of Principal Executive Offices) (Zip Code)</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(<ix:nonNumeric contextRef="d20248K" name="dei:CityAreaCode" id="ixv-365">510</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="d20248K" name="dei:LocalPhoneNumber" id="ixv-366">899-8800</ix:nonNumeric></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(Registrant</b>&#8217;<b>s telephone number, including area code)</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><ix:nonNumeric contextRef="d20248K" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="ixv-367">&#9744;</ix:nonNumeric></div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</div>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&#160;</td>
			<td style="width: auto;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</div>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><ix:nonNumeric contextRef="d20248K" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="ixv-368">&#9744;</ix:nonNumeric></div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</div>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&#160;</td>
			<td style="width: auto;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</div>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><ix:nonNumeric contextRef="d20248K" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="ixv-369">&#9744;</ix:nonNumeric></div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</div>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&#160;</td>
			<td style="width: auto;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</div>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><ix:nonNumeric contextRef="d20248K" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="ixv-370">&#9744;</ix:nonNumeric></div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Securities registered pursuant to Section 12(b) of the Act:</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:bottom;width:36%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><span style="text-decoration: underline;">Title of Each Class</span></b></div>
			</td>
			<td style="vertical-align:bottom;width:1.4%;">&#160;</td>
			<td style="vertical-align:bottom;width:24.9%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><span style="text-decoration: underline;">Trading Symbol(s)</span></b></div>
			</td>
			<td style="vertical-align:top;width:1.6%;">&#160;</td>
			<td style="vertical-align:bottom;width:36%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><span style="text-decoration: underline;">Name of Each Exchange On Which Registered</span></b></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:36%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20248K" name="dei:Security12bTitle" id="ixv-371">Common Stock</ix:nonNumeric>, par value $0.01 per share</div>
			</td>
			<td style="vertical-align:bottom;width:1.4%;">&#160;</td>
			<td style="vertical-align:top;width:24.9%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20248K" name="dei:TradingSymbol" id="ixv-372">NBY</ix:nonNumeric></div>
			</td>
			<td style="vertical-align:top;width:1.6%;">&#160;</td>
			<td style="vertical-align:top;width:36%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20248K" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="ixv-373">NYSE</ix:nonNumeric>&#160;American</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#8201;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#8201;240.12b-2 of this chapter). Emerging growth company&#160;<ix:nonNumeric contextRef="d20248K" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="ixv-374">&#9744;</ix:nonNumeric></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#9744;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&#160;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">&#160;</div>
</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 72pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>Item</b><b> 1.01 </b></div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>Entry into a Material Definitive Agreement</b></div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">On June 14, 2024, NovaBay Pharmaceuticals, Inc. (the &#8220;<i>Company</i>&#8221;) announced that as of June 14, 2024, it entered into letter agreements (the &#8220;<i>Letter Agreements</i>&#8221;) with certain existing holders of its (i) (i) warrants issued in September 2022 (the &#8220;<i>September 2022 Warrants</i>&#8221;) to purchase common stock, par value $0.01 per share (&#8220;<i>Common Stock</i>&#8221;); (ii) Series A-1 warrants issued in November 2022 (the &#8220;<i>Series A-1 Warrants</i>&#8221;) to purchase Common Stock; (iii) Series B-1 warrants issued in May 2023 (the &#8220;<i>Series B-1 Warrants</i>&#8221;) to purchase Common Stock; and (iv) Series B-2 warrants issued in May 2023 (the &#8220;<i>Series B-2 Warrants</i>&#8221;) to purchase Common Stock (collectively (i) through (iv), the &#8220;<i>Existing Warrants</i>&#8221;). The holders of the Existing Warrants that entered into Letter Agreements are referred to in this Current Report on Form 8-K as the &#8220;<i>Participants</i>&#8221;.</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</div>

<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The Letter Agreements provide for the following (which are collectively referred to as the &#8220;<i>Warrant Reprice Transactions</i>&#8221;):</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</div>

<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Warrant Exercise</b></div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Pursuant to the terms of the Letter Agreements, the Participants agreed to make an exercise (the&#160;&#8220;<i>Warrant Exercise</i>&#8221;) of a portion of their Existing Warrants at a reduced exercise price of $2.50 (the &#8220;<i>Reduced Exercise Price</i>&#8221;) (as reduced from the exercise price pursuant to the terms of the Existing Warrants). There were an aggregate of approximately 90,381 shares of Common Stock underlying the Existing Warrants that were exercised in connection with the Warrant Exercise, resulting in gross proceeds to the Company of approximately $225,952.</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</div>

<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The closing of the Warrant Exercise is expected to occur on June 17, 2024. The resale of the shares of Common Stock underlying the Existing Warrants (&#8220;<i>Warrant Shares</i>&#8221;) have been previously registered pursuant to registration statements on Form S-1 that are on file with the U.S. Securities and Exchange Commission (the &#8220;<i>Commission</i>&#8221;).</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</div>

<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>New Series E Common Stock Purchase Warrants</b></div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</div>

<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">As a result of the Warrant Exercise, the Company will issue a new Series E Common Stock purchase warrant (the &#8220;<i>New Warrants</i>&#8221;) to each Participant to purchase a number of shares of Common Stock equal to 100% of the shares of Common Stock received by such Participant in the Warrant Exercise.</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</div>

<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The New Warrants are substantially similar to the Existing Warrants, except that the New Warrants will (i) be initially exercisable on the six-month anniversary of the date of issuance; (ii) have an exercise price of $2.57; and (iii) have a term of five (5) years and six (6) months from the date of the closing of the Warrant Reprice Transactions.</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</div>

<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The Letter Agreements also provide that on or prior to ninety (90) days after the closing of the Warrant Reprice Transactions, the Company will prepare and file a registration statement with the Commission covering the resale of 100% of the Common Stock underlying the New Warrants issued to the Participants (the &#8220;<i>New Warrant Shares</i>&#8221;).</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The foregoing summaries of the material terms of the New Warrants and the Letter Agreements&#160;are qualified in their entirety by reference to the full text of the New Warrants and the Letter Agreements, forms of which are filed herewith as Exhibits 4.1 and 10.1, respectively, and incorporated herein by reference.</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</div>

<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Private Placement Exemption</b></div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</div>

<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">None of the issuance of the New Warrants and/or the New Warrant Shares in the Warrant Reprice Transactions (collectively, the &#8220;<i>Securities</i>&#8221;), have been or will be registered at the time of issuance by the Company under the Securities Act of 1933, as amended (the &#8220;<i>Securities Act</i>&#8221;), and such securities may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements. The Company is relying on the private placement exemption from registration provided by Section 4(a)(2) of the Securities Act, and by Rule 506 of Regulation D promulgated thereunder, and in reliance on similar exemptions under applicable state laws. No form of general solicitation or general advertising was conducted in connection with the issuance of the Securities in the Warrant Reprice Transactions. The Securities issued in each of these private placement transactions contain (or will contain, where applicable) restrictive legends preventing the sale, transfer, or other disposition of such Securities, unless registered under the Securities Act, or pursuant to an exemption therefrom. The disclosure contained in this Current Report on Form 8-K does not constitute an offer to sell or a solicitation of an offer to buy any securities of the Company, and is made only as required under applicable rules for filing current reports with the Commission.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&#160;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">&#160;</div>
</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Placement Agent</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Ladenburg Thalmann &amp; Co. Inc. (&#8220;<i>Ladenburg</i>&#8221;) agreed to serve as the Company's exclusive warrant solicitation agent and exclusive placement agent for the Warrant Reprice Transactions, in exchange for a fee equal to 8% of the total gross proceeds to the Company from the Warrant Reprice Transactions, subject to certain exclusions. The Company also agreed to reimburse Ladenburg for certain related expenses in an amount not to exceed $50,000 in the aggregate.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Additional Matters</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The documents entered into in connection with the Warrant Reprice Transactions described above and/or attached as an exhibit to this Current Report on Form 8-K (collectively, the &#8220;<i>Transaction Documents</i>&#8221;) contain representations and warranties of the parties to such agreements that may be subject to limitations, qualifications or exceptions agreed upon by the parties, and may be subject to a contractual standard of materiality that differs from the materiality standard that applies to reports and documents filed with the Commission. In particular, in your review of the representations and warranties contained in the Transaction Documents and described in the foregoing summary, it is important to bear in mind that the representations and warranties were negotiated in connection with separate transactions and with the principal purpose of allocating contractual risk between the parties in such transactions. The representations and warranties, other provisions of the Transaction Documents or any description of these provisions should not be read alone, but instead should be read only in conjunction with the information provided elsewhere in this Current Report on Form 8-K and in the other reports, statements and filings that the Company publicly files with the Commission.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 72pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>Item 3</b><b>.02</b></div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>Unregistered Sales of Equity Securities</b></div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The information disclosed in Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Cautionary Language Concerning Forward-Looking Statements</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">This Current Report on Form 8-K contains forward-looking statements within the meaning of the &#8220;safe harbor&#8221; provisions of the Private Securities Litigation Reform Act of 1995, including statements about the timing and expected impact of the Warrant Reprice Transactions. These forward-looking statements are based upon management&#8217;s current expectations, assumptions, estimates, projections and beliefs. These statements involve risks, uncertainties and other factors that may cause actual results or achievements to be materially different and adverse from those expressed in or implied by these forward-looking statements. Other risks relating to the Company&#8217;s business, including risks that could cause results to differ materially from those projected in the forward-looking statements in this Current Report on Form 8-K, are detailed in the Company&#8217;s latest Form 10-K, subsequent Forms 10-Q and/or Form 8-K filings with the Commission, especially under the heading &#8220;Risk Factors.&#8221; The forward-looking statements in this Current Report on Form 8-K speak only as of this date, and the Company disclaims any intent or obligation to revise or update publicly any forward-looking statement except as required by law.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 72pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>Item</b><b> 9.01.</b></div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>Financial Statements and Exhibits.</b></div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:10.2%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(d)</div>
			</td>
			<td style="vertical-align:top;width:89.8%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline;">Exhibits.</span></div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:middle;width:8%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Exhibit No.</b></div>
			</td>
			<td style="vertical-align:middle;width:2%;">&#160;</td>
			<td style="vertical-align:middle;width:90%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Description</b></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:8%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">4.1</div>
			</td>
			<td style="vertical-align:middle;width:2%;">&#160;</td>
			<td style="vertical-align:middle;width:90%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_688392.htm" style="-sec-extract:exhibit;">Form of Series E Common Stock Warrant</a></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:8%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10.1</div>
			</td>
			<td style="vertical-align:middle;width:2%;">&#160;</td>
			<td style="vertical-align:middle;width:90%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_688393.htm" style="-sec-extract:exhibit;">Form of Letter Agreement, dated June 14, 2024</a></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:8%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">104</div>
			</td>
			<td style="vertical-align:middle;width:2%;">&#160;</td>
			<td style="vertical-align:middle;width:90%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&#160;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">&#160;</div>
</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>SIGNATURES</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:23.1%;">&#160;</td>
			<td colspan="2" style="vertical-align:top;width:17.6%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>NovaBay Pharmaceuticals, Inc.</b></div>
			</td>
			<td style="vertical-align:top;width:5.6%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:23.1%;">&#160;</td>
			<td style="vertical-align:top;width:1.4%;">&#160;</td>
			<td style="vertical-align:bottom;width:16.2%;">&#160;</td>
			<td style="vertical-align:top;width:5.6%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:23.1%;">&#160;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:top;width:1.4%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">By:</div>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:top;width:16.2%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/&#160;Justin M. Hall</div>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:top;width:5.6%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:23.1%;">&#160;</td>
			<td style="vertical-align:top;width:1.4%;">&#160;</td>
			<td style="vertical-align:top;width:16.2%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Justin M. Hall</div>
			</td>
			<td style="vertical-align:top;width:5.6%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:23.1%;">&#160;</td>
			<td style="vertical-align:top;width:1.4%;">&#160;</td>
			<td style="vertical-align:top;width:16.2%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Chief Executive Officer and General Counsel</div>
			</td>
			<td style="vertical-align:top;width:5.6%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:23.1%;">&#160;</td>
			<td style="vertical-align:top;width:1.4%;">&#160;</td>
			<td style="vertical-align:top;width:16.2%;">&#160;</td>
			<td style="vertical-align:top;width:5.6%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:23.1%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Dated: June 14, 2024</div>
			</td>
			<td style="vertical-align:top;width:1.4%;">&#160;</td>
			<td style="vertical-align:top;width:16.2%;">&#160;</td>
			<td style="vertical-align:top;width:5.6%;">&#160;</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&#160;</div>
</div>
</div>
</div>


</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>2
<FILENAME>ex_688392.htm
<DESCRIPTION>EXHIBIT 4.1
<TEXT>
<html><head>
	<title>ex_688392.htm</title>

	<!-- Generated by ThunderDome Portal - 6/14/2024 1:44:17 AM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<div contenteditable="false" data-applyto="t" data-auto-pgnum="start" data-displaynum="1" data-fontname="Times New Roman" data-fontsize="10pt" data-numstyle="a" data-prefix="" data-startnum="1" data-suffix="" data-textalign="center">&nbsp;</div>

<p style="margin: 0px 0pt; text-align: right; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 4.1</b></font></p>

<p style="margin: 0px 0pt; text-align: left; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &#8220;SECURITIES ACT&#8221;), OR UNDER ANY STATE SECURITIES OR BLUE SKY LAWS. THE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE, AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. INVESTORS SHOULD BE AWARE THAT THEY MAY BE REQUIRED TO BEAR THE FINANCIAL RISKS OF THIS INVESTMENT FOR AN INDEFINITE PERIOD OF TIME. THE COMPANY MAY REQUIRE AN OPINION OF COUNSEL IN FORM AND SUBSTANCE REASONABLY SATISFACTORY TO THE COMPANY TO THE EFFECT THAT ANY PROPOSED TRANSFER IS IN COMPLIANCE WITH THE SECURITIES ACT. THIS SECURITY IS SUBJECT TO THE TRANSFER RESTRICTIONS SET FORTH HEREIN AND IN THE LETTER AGREEMENT, DATED JUNE 14, 2024, AS AMENDED FROM TIME TO TIME, COPIES OF WHICH ARE AVAILABLE WITH THE SECRETARY OF THE COMPANY. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT WITH A REGISTERED BROKER-DEALER OR OTHER LOAN WITH A FINANCIAL INSTITUTION THAT IS AN &#8220;ACCREDITED INVESTOR&#8221; AS DEFINED IN RULE 501(A) UNDER THE SECURITIES ACT OR OTHER LOAN SECURED BY SUCH SECURITIES.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>NOVABAY PHARMACEUTICALS, INC.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>SERIES E COMMON STOCK PURCHASE WARRANT</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family: Times New Roman; font-size: 10pt; width: 100%;">

		<tr>
			<td style="vertical-align:top;width:51.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Warrant Shares: [&#9679;]</p>
			</td>
			<td style="vertical-align:top;width:51.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">Issue Date: June 17, 2024</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">THIS SERIES E COMMON STOCK PURCHASE WARRANT (the &#8220;<u>Warrant</u>&#8221;) certifies that, for value received, [&#9679;] or its assigns (the &#8220;<u>Holder</u>&#8221;) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after December 17, 2024 ( &#8220;<u>Initial Exercise Date</u>&#8221;), and (b) on or prior to 5:00 p.m. (New York City time) on December 17, 2029 (the&nbsp;&#8220;<u>Termination Date</u>&#8221;) but not thereafter, to subscribe for and purchase from NovaBay Pharmaceuticals, Inc., a Delaware corporation (the &#8220;<u>Company</u>&#8221;), up to [&#9679;] shares (as subject to adjustment hereunder, the &#8220;<u>Warrant Shares</u>&#8221;) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><u>Section 1</u>.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Definitions</u>. Unless otherwise specified, capitalized terms used and not otherwise defined herein shall have the meanings set forth in (x) that certain Securities Purchase Agreement (the &#8220;<u>Purchase Agreement</u>&#8221;), dated [&#9679;], between the Company and each purchaser that is a signatory thereto, including the Holder and (y) the letter agreement, dated June 14, 2024, between the Holder and the Company (the &#8220;<u>Letter Agreement</u>&#8221;).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="1" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">1</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><u>Section 2</u>.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Exercise</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">a)&nbsp;&nbsp;&nbsp;&nbsp;<u>Exercise of Warrant</u>. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed facsimile copy or PDF copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise in the form attached hereto as Exhibit A (the &#8220;<u>Notice of Exercise</u>&#8221;). Within the earlier of (i) one (1) Trading Day and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined in Section 2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the shares specified in the applicable Notice of Exercise by wire transfer or cashier&#8217;s check drawn on a United States bank, unless the cashless exercise procedure specified in Section 2(c) below is specified in the applicable Notice of Exercise.<b> </b>No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise be required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation within three (3) Trading Days of the date on which the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice of Exercise within one (1) Business Day of receipt of such notice. <b>The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof.</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">b)&nbsp;&nbsp;&nbsp;&nbsp;<u>Exercise Price</u>. The exercise price per share of Common Stock under this Warrant shall be <b>$2.57</b>, subject to adjustment hereunder (the &#8220;<u>Exercise Price</u>&#8221;).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">c)&nbsp;&nbsp;&nbsp;&nbsp;<u>Cashless Exercise</u>. After the Initial Exercise Date, if there is no effective registration statement registering, or no current prospectus available for, the resale of the Warrant Shares by the Holder, then this Warrant may also be exercised, in whole or in part, at such time by means of a &#8220;cashless exercise&#8221; in which the Holder shall be entitled to receive a number of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="2" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">2</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 99pt; text-indent: -27pt; text-align: justify;">(A) = as applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of Exercise is (1) both executed and delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) both executed and delivered pursuant to Section 2(a) hereof on a Trading Day prior to the opening of &#8220;regular trading hours&#8221; (as defined in Rule 600(b) of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii) at the option of the Holder, either (y) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise or (z) the Bid Price of the Common Stock on the principal Trading Market as reported by Bloomberg L.P. as of the time of the Holder&#8217;s execution of the applicable Notice of Exercise if such Notice of Exercise is executed during &#8220;regular trading hours&#8221; on a Trading Day and is delivered within two (2) hours thereafter (including until two (2) hours after the close of &#8220;regular trading hours&#8221; on a Trading Day) pursuant to Section 2(a) hereof or (iii) the VWAP on the date of the applicable Notice of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to Section 2(a) hereof after the close of &#8220;regular trading hours&#8221; on such Trading Day;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 108pt; text-indent: -36pt; text-align: justify;">(B) = the Exercise Price of this Warrant, as adjusted hereunder; and</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 104pt; text-indent: -32pt; text-align: justify;">(X) = the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise were by means of a cash exercise rather than a cashless exercise.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">If Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the Securities Act, the Warrant Shares shall take on the characteristics of the Warrants being exercised, and the holding period of the Warrant Shares being issued may be tacked on to the holding period of this Warrant.&nbsp;The Company agrees not to take any position contrary to this Section 2(c).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">&#8220;<u>Bid Price</u>&#8221; means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the Pink Open Market (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d)&nbsp;in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Holder and Other Holders (both as defined in the Letter Agreement) who participate and enter into similar letter agreements as the Holder of a majority in interest of the Exercised Warrant Shares (as defined in the Letter Agreement) and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="3" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">3</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">&#8220;<u>VWAP</u>&#8221; means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the Pink Open Market (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d)&nbsp;in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Holder and Other Holders (both as defined in the Letter Agreement) who participate and enter into similar letter agreements as the Holder of a majority in interest of the Exercised Warrant Shares and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 72pt; text-align: justify;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">d)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><u>Mechanics of Exercise</u>.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 99pt; text-indent: 36pt; text-align: justify;">i.&nbsp;&nbsp;&nbsp;&nbsp;<u>Delivery of Warrant Shares Upon Exercise</u>. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by the Transfer Agent to the Holder by crediting the account of the Holder&#8217;s or its designee&#8217;s balance account with The Depository Trust Company through its Deposit or Withdrawal at Custodian system (&#8220;<u>DWAC</u>&#8221;) if the Company is then a participant in such system and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to or resale of the Warrant Shares by the Holder or (B) the Warrant Shares are eligible for resale by the Holder without volume or manner-of-sale limitations pursuant to Rule 144 (assuming cashless exercise of the Warrants), and otherwise by physical delivery of a certificate, registered in the Company&#8217;s share register in the name of the Holder or its designee, for the number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the date that is the earlier of (i) one (1) Trading Day after the delivery to the Company of the Notice of Exercise and (ii) the number of Trading Days comprising the Standard Settlement Period after the delivery to the Company of the Notice of Exercise (such date, the &#8220;<u>Warrant Share Delivery Date</u>&#8221;). Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares, provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received within the earlier of (i) one (1) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period following delivery of the Notice of Exercise. If the Company fails for any reason to deliver to the Holder the Warrant Shares subject to a Notice of Exercise by the Warrant Share Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares subject to such exercise (based on the VWAP of the Common Stock on the date of the applicable Notice of Exercise), $2.50 per Trading Day (increasing to $15 per Trading Day on the fifth Trading Day after such liquidated damages begin to accrue) for each Trading Day after such Warrant Share Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise. The Company agrees to maintain a transfer agent that is a participant in the FAST program so long as this Warrant remains outstanding and exercisable. As used herein, &#8220;<u>Standard Settlement Period</u>&#8221; means the standard settlement period, expressed in a number of Trading Days, on the Company&#8217;s primary Trading Market with respect to the Common Stock as in effect on the date of delivery of the Notice of Exercise.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="4" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">4</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 99pt; text-indent: 36pt; text-align: justify;">ii.&nbsp;&nbsp;&nbsp;&nbsp;<u>Delivery of New Warrants Upon Exercise</u>. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects be identical with this Warrant.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 99pt; text-indent: 36pt; text-align: justify;">iii.&nbsp;&nbsp;&nbsp;&nbsp;<u>Rescission Rights</u>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section 2(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 99pt; text-indent: 36pt; text-align: justify;">iv.&nbsp;&nbsp;&nbsp;&nbsp;<u>Compensation for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise</u>. In addition to any other rights available to the Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions of Section 2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder is required by its broker to purchase (in an open market transaction or otherwise) or the Holder&#8217;s brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a &#8220;<u>Buy-In</u>&#8221;), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder&#8217;s total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained by multiplying (1) the number of Warrant Shares that the Company was required to deliver to the Holder (up to the number of shares of Common Stock required to be purchased by the Holder or its broker for the Buy-In) in connection with a valid exercise, and (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares of Common Stock with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit a Holder&#8217;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company&#8217;s failure to timely deliver shares of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="5" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">5</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 99pt; text-indent: 36pt; text-align: justify;">v.&nbsp;&nbsp;&nbsp;&nbsp;<u>No Fractional Shares or Scrip</u>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Exercise Price or round up to the next whole share.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 99pt; text-indent: 36pt; text-align: justify;">vi.&nbsp;&nbsp;&nbsp;&nbsp;<u>Charges, Taxes and Expenses</u>. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company, and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder in the Notice of Exercise; <u>provided</u>, <u>however</u>, that in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached hereto as <u>Exhibit B</u> duly executed by the Holder and the Company shall have the right to require, as a condition thereto, the prior or contemporaneous payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company (or another established clearing corporation performing similar functions) required for same-day electronic delivery of the Warrant Shares, in each case, to the extent available.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="6" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">6</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 99pt; text-indent: 36pt; text-align: justify;">vii.&nbsp;&nbsp;&nbsp;&nbsp;<u>Closing of Books</u>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant, pursuant to the terms hereof.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 72pt; text-align: justify;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">e)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><u>Holder</u><u>&#8217;</u><u>s Exercise Limitations</u>. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&#8217;s Affiliates, and any other Persons acting as a group together with the Holder or any of the Holder&#8217;s Affiliates (such Persons, &#8220;<u>Attribution Parties</u>&#8221;)), would beneficially own in excess of the Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its Attribution Parties shall include the number of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant beneficially owned by the Holder or any of its Attribution Parties and (ii) exercise or conversion of the unexercised or nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its Attribution Parties. Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent that the limitation contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Attribution Parties) and of which portion of this Warrant is exercisable up to the Beneficial Ownership Limitation shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder&#8217;s good faith determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Attribution Parties) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy of such determination. In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, and the Company shall have no obligation to verify or confirm the accuracy of such determination and shall have no liability for exercises of the Warrant that are not in compliance with the Beneficial Ownership Limitation (other than as a result of a Holder&#8217;s reliance on the number of issued and outstanding shares of Common Stock pursuant to this Section 2(e)). For purposes of this Section 2(e), in determining the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected in (A) the Company&#8217;s most recent periodic or annual report filed with the Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding. Upon the written request of a Holder, the Company shall within one (1) Trading Day confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder or Attribution Parties since the date as of which such number of outstanding shares of Common Stock was reported. The &#8220;<u>Beneficial Ownership Limitation</u>&#8221;&nbsp;shall be 4.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon exercise of this Warrant. The Holder, upon prior written notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section 2(e), provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon exercise of this Warrant held by the Holder and the provisions of this Section 2(e) shall continue to apply. Any such increase or decrease in the Beneficial Ownership Limitation will apply only to the Holder and not to any other holder of Warrants. Any such increase in the Beneficial Ownership Limitation will not be effective until the 61st day after such notice is delivered to the Company. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 2(e) to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph shall apply to a successor holder of this Warrant.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="7" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">7</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><u>Section 3</u>.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Certain Adjustments</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">a)&nbsp;&nbsp;&nbsp;&nbsp;<u>Stock Dividends and Splits</u>. If the Company, at any time on or after the Issue Date and while this Warrant is outstanding: (i) pays a stock dividend or otherwise makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon (x) exercise of this Warrant or any other Company warrant, (y) conversion of, or payment of interest on, any convertible debentures of the Company or (z) conversion of, or payment of any dividend on, Company preferred stock, (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares or (iv) issues by reclassification of shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the date such dividend or distribution occurs and shall become effective immediately after the effective date in the case of a subdivision, combination or re&#8209;classification.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">b)&nbsp;&nbsp;&nbsp;&nbsp;<u>Subsequent Rights Offerings</u>. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants, issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record holders of any class of shares of Common Stock (the &#8220;<u>Purchase Rights</u>&#8221;), then the Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (<u>provided</u>, <u>however</u>, that, to the extent that the Holder&#8217;s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="8" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">8</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">c)&nbsp;&nbsp;&nbsp;&nbsp;<u>Pro Rata Distributions</u>. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a &#8220;<u>Distribution</u>&#8221;), at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution (<u>provided</u>, <u>however</u>, that, to the extent that the Holder's right to participate in any such Distribution would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">d)&nbsp;&nbsp;&nbsp;&nbsp;<u>Fundamental Transaction</u>. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company, directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding Common Stock, (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off, merger or scheme of arrangement) with another Person or group of Persons whereby such other Person or group acquires more than 50% of the outstanding shares of Common Stock (each a &#8220;Fundamental Transaction&#8221;), then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without regard to any limitation in Section 2(e) on the exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration (the &#8220;Alternate Consideration&#8221;) receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant is exercisable immediately prior to such Fundamental Transaction (without regard to any limitation in Section 2(e) on the exercise of this Warrant). For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction. Notwithstanding anything to the contrary, in the event of a Fundamental Transaction, the Company or any Successor Entity (as defined below) shall, at the Holder&#8217;s option, exercisable at any time concurrently with, or within thirty (30) days after, the consummation of the Fundamental Transaction (or, if later, the date of the public announcement of the applicable Fundamental Transaction), purchase this Warrant from the Holder for the same type or form of consideration (and in the same proportion), as the Black Scholes Value of the unexercised portion of the Warrant, that is being offered and paid to the holders of Common Stock of the Company in connection with the Fundamental Transaction, whether that consideration be in the form of cash, stock or any combination thereof, or whether the holders of Common Stock are given the choice to receive from among alternative forms of consideration in connection with the Fundamental Transaction. &#8220;Black Scholes Value&#8221; means the value of this Warrant based on the Black-Scholes Option Pricing Model obtained from the &#8220;OV&#8221; function on Bloomberg, L.P. (&#8220;Bloomberg&#8221;) determined as of the day of consummation of the applicable Fundamental Transaction for pricing purposes and reflecting (A) a risk-free interest rate corresponding to the U.S. Treasury rate for a period equal to the time between the date of the public announcement of the applicable Fundamental Transaction and the Termination Date, (B) an expected volatility equal to the greater of 100% and the 100 day volatility obtained from the HVT function on Bloomberg (determined utilizing a 365 day annualization factor) as of the Trading Day immediately following the public announcement of the applicable Fundamental Transaction, (C) the underlying price per share used in such calculation shall be the greater of (i) the sum of the price per share being offered in cash, if any, plus the value of any non-cash consideration, if any, being offered in such Fundamental Transaction and (ii) the greater of (x) the last VWAP immediately prior to the public announcement of such Fundamental Transaction and (y) the last VWAP immediately prior to the consummation of such Fundamental Transaction, (D) a remaining option time equal to the time between the date of the public announcement of the applicable Fundamental Transaction and the Termination Date, and (E) a zero cost of borrow. The payment of the Black Scholes Value will be made by wire transfer of immediately available funds within five Business Days of the Holder&#8217;s election (or, if later, on the effective date of the Fundamental Transaction). The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor (the &#8220;Successor Entity&#8221;) to assume in writing all of the obligations of the Company under this Warrant and the other Transaction Documents in accordance with the provisions of this Section 3(d) pursuant to written agreements in form and substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder to such shares of capital stock (but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock and such exercise price being for the purpose of protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for the Company (so that from and after the date of such Fundamental Transaction, the provisions of this Warrant and the other Transaction Documents referring to the &#8220;Company&#8221; shall refer instead to the Successor Entity), and the Successor Entity may exercise every right and power of the Company and shall assume all of the obligations of the Company under this Warrant and the other Transaction Documents with the same effect as if such Successor Entity had been named as the Company herein.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="9" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">9</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">e)&nbsp;&nbsp;&nbsp;&nbsp;<u>Calculations</u>. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 72pt; text-align: justify;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">f)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><u>Notice to Holder</u>.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 99pt; text-indent: 36pt; text-align: justify;">i.&nbsp;&nbsp;&nbsp;&nbsp;<u>Adjustment to Exercise Price</u>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall promptly deliver to the Holder by facsimile or email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 99pt; text-indent: 36pt; text-align: justify;">ii.&nbsp;&nbsp;&nbsp;&nbsp;<u>Notice to Allow Exercise by Holder</u>. If during the term in which the Warrant may be exercised (A) the Company shall declare a dividend (or any other distribution in whatever form) on the Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with any reclassification of the Common Stock, any consolidation or merger to which the Company is a party, any sale or transfer of all or substantially all of the assets of the Company, or any compulsory share exchange whereby the Common Stock is converted into other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by facsimile or email to the Holder at its last facsimile number or email address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to be specified in such notice. To the extent that any notice provided in this Warrant constitutes, or contains, material, non-public information regarding the Company or any of the Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K. The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="10" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">10</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">g)&nbsp;&nbsp;&nbsp;&nbsp;<u>Voluntary Adjustment By Company</u>. Subject to the rules and regulations of the Trading Market, the Company may at any time during the term of this Warrant reduce the then current Exercise Price to any amount and for any period of time deemed appropriate by the Board of Directors of the Company.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><u>Section 4</u>.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Transfer of Warrant</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">a)&nbsp;&nbsp;&nbsp;&nbsp;<u>Transferability</u>. Subject to compliance with any applicable securities laws and the conditions set forth in Section 4(d) hereof and to the provisions of Section (f) of Annex A to the Letter Agreement, this Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable, in whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment of this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant as provided herein, in which case, the Holder shall surrender this Warrant to the Company within three (3) Trading Days of the date on which the Holder delivers an Assignment Form (in the form attached hereto as <u>Exhibit B</u>) to the Company assigning this Warrant. The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for the purchase of Warrant Shares without having a new Warrant issued.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="11" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">11</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">b)&nbsp;&nbsp;&nbsp;&nbsp;<u>New Warrants</u>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the original Issue Date and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">c)&nbsp;&nbsp;&nbsp;&nbsp;<u>Warrant Register</u>. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the &#8220;<u>Warrant Register</u>&#8221;), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">d)&nbsp;&nbsp;&nbsp;&nbsp;<u>Transfer Restrictions</u>. If, at the time of the surrender of this Warrant in connection with any transfer of this Warrant, the transfer of this Warrant shall not be either (i) registered pursuant to an effective registration statement under the Securities Act and under applicable state securities or blue sky laws or (ii) eligible for resale without volume or manner-of-sale restrictions or current public information requirements pursuant to Rule 144, the Company may require, as a condition of allowing such transfer, that the Holder or transferee of this Warrant, as the case may be, comply with the provisions of Section (f) of Annex A to the Letter Agreement.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">e)&nbsp;&nbsp;&nbsp;&nbsp;<u>Representation by the Holder</u>. The Holder, by the acceptance hereof, represents and warrants that it is acquiring this Warrant and, upon any exercise hereof, will acquire the Warrant Shares issuable upon such exercise, for its own account and not with a view to or for distributing or reselling such Warrant Shares or any part thereof in violation of the Securities Act or any applicable state securities law, except pursuant to sales registered or exempted under the Securities Act.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><u>Section 5</u>.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Miscellaneous</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">a)&nbsp;&nbsp;&nbsp;&nbsp;<u>No Rights as Stockholder Until Exercise; No Settlement in Cash</u>. This Warrant does not entitle the Holder to any voting rights, dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly set forth in Section 3. Without limiting any rights of a Holder to receive Warrant Shares on a &#8220;cashless exercise&#8221; pursuant to Section 2(c) or to receive cash payments pursuant to Section 2(d)(i) and Section 2(d)(iv) herein, in no event shall the Company be required to net cash settle an exercise of this Warrant.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="12" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">12</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">b)&nbsp;&nbsp;&nbsp;&nbsp;<u>Loss, Theft, Destruction or Mutilation of Warrant</u>. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">c)&nbsp;&nbsp;&nbsp;&nbsp;<u>Saturdays, Sundays, Holidays, etc</u>. If the last or appointed day for the taking of any action or the expiration of any right required or granted herein shall not be a Business Day, then, such action may be taken or such right may be exercised on the next succeeding Business Day.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">d)&nbsp;&nbsp;&nbsp;&nbsp;<u>Authorized Shares</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-indent: 36pt; text-align: justify;">The Company covenants that during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant. The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants that all Warrant Shares which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously with such issue).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-indent: 36pt; text-align: justify;">Except and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the Company will, so long as any of the Warrants are outstanding, (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations under this Warrant.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="13" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">13</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt; text-indent: 36pt; text-align: justify;">Before taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory body or bodies having jurisdiction thereof.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">e)&nbsp;&nbsp;&nbsp;&nbsp;<u>Jurisdiction</u>. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be determined in accordance with the provisions of the Purchase Agreement.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">f)&nbsp;&nbsp;&nbsp;&nbsp;<u>Restrictions</u>. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered and the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">g)&nbsp;&nbsp;&nbsp;&nbsp;<u>Nonwaiver and Expenses</u>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as a waiver of such right or otherwise prejudice the Holder&#8217;s rights, powers or remedies. Without limiting any other provision of this Warrant, the Purchase Agreement, or the Letter Agreement, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including, but not limited to, reasonable attorneys&#8217; fees, including those of appellate proceedings, incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">h)&nbsp;&nbsp;&nbsp;&nbsp;<u>Notices</u>. Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company shall be delivered in accordance with the notice provisions of the Purchase Agreement.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">i)&nbsp;&nbsp;&nbsp;&nbsp;<u>Limitation of Liability</u>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the Company.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="14" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">14</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">j)&nbsp;&nbsp;&nbsp;&nbsp;<u>Remedies</u>. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any action for specific performance that a remedy at law would be adequate.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">k)&nbsp;&nbsp;&nbsp;&nbsp;<u>Successors and Assigns</u>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable by the Holder or holder of Warrant Shares.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">l)&nbsp;&nbsp;&nbsp;&nbsp;<u>Amendment</u>. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and the Holder.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">m)&nbsp;&nbsp;&nbsp;&nbsp;<u>Severability</u>. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt; text-align: justify;">n)&nbsp;&nbsp;&nbsp;&nbsp;<u>Headings</u>. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">********************</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i>(Signature Page Follows)</i></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" data-number="15" data-prefix="" data-suffix="" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">15</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:72pt;">IN WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:9pt;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 47.0588%; margin-left: auto; margin-right: 0pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>NOVABAY PHARMACEUTICALS, INC.</b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">By:__________________________________________</p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Name: Justin Hall</p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -18pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Title: Chief Executive Officer and General Counsel</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;text-indent:9pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="16" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">16</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<div contenteditable="false" data-auto-pgnum="end">&nbsp;</div>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b>EXHIBIT A</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>NOTICE OF EXERCISE</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">TO:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NOVABAY PHARMACEUTICALS, INC.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;">(1)&nbsp;&nbsp;&nbsp;&nbsp;The undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;">(2)&nbsp;&nbsp;&nbsp;&nbsp;Payment shall take the form (check applicable box):</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 108pt;">[&nbsp; ] in lawful money of the United States; or</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 108pt;">[&nbsp; ] if permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in subsection 2(c).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;">(3)&nbsp;&nbsp;&nbsp;&nbsp;Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 81pt; text-indent: 27pt;">_______________________________</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;text-indent:27pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Warrant Shares shall be delivered to the following DWAC Account Number:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="width: 50%; padding-left: 18pt;">Broker Name:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</td>
			<td style="width: 50%; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
		</tr>
		<tr>
			<td>&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr>
			<td style="padding-left: 18pt;">Broker DTC DWAC #:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
		</tr>
		<tr>
			<td>&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr>
			<td style="padding-left: 18pt;">Broker Contact:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
		</tr>
		<tr>
			<td>&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr>
			<td style="padding-left: 18pt;">Account #:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt;">(4) <u>Accredited Investor</u>. The undersigned warrants that it is an &#8220;accredited investor&#8221; as defined in Regulation D promulgated under the Securities Act of 1933, as amended, and that the Warrant Shares issued pursuant to this Notice of Exercise will not cause the undersigned to exceed the Beneficial Ownership Limitation.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">[SIGNATURE OF HOLDER]</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="width: 50%;">Name of Investing Entity:</td>
			<td style="width: 50%; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
		</tr>
		<tr>
			<td>Signature of Authorized Signatory of Investing Entity:</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
		</tr>
		<tr>
			<td>Name of Authorized Signatory:</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
		</tr>
		<tr>
			<td>Title of Authorized Signatory:</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
		</tr>
		<tr>
			<td>Date:</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b>EXHIBIT B</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">ASSIGNMENT FORM</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:11pt;"><i>(To assign the foregoing Warrant, execute this form and supply required information. Do not use this form to purchase shares.)</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:11pt;">FOR VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family: Times New Roman; font-size: 10pt; width: 100%;">

		<tr>
			<td style="vertical-align:top;width:50.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Name:</p>
			</td>
			<td style="vertical-align: top; width: 50.6%; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:50.6%;">&nbsp;</td>
			<td style="vertical-align:top;width:50.6%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">(Please Print)</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:50.6%;">&nbsp;</td>
			<td style="vertical-align:top;width:50.6%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:50.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Address:</p>
			</td>
			<td style="vertical-align: top; width: 50.6%; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:50.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:9pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:50.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(Please Print)</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:50.6%;">&nbsp;</td>
			<td style="vertical-align:top;width:50.6%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:50.6%;">Phone Number:</td>
			<td style="vertical-align: top; width: 50.6%; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:50.6%;">&nbsp;</td>
			<td style="vertical-align:top;width:50.6%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:50.6%;">Email Address:</td>
			<td style="vertical-align: top; width: 50.6%; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:50.6%;">&nbsp;</td>
			<td style="vertical-align:top;width:50.6%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:50.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Dated: _______________ __, ______</p>
			</td>
			<td style="vertical-align:top;width:50.6%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:50.6%;">&nbsp;</td>
			<td style="vertical-align:top;width:50.6%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:50.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Holder&#8217;s Signature:&nbsp;&nbsp;&nbsp;&nbsp;<u>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp; &nbsp; </u></p>
			</td>
			<td style="vertical-align:top;width:50.6%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:50.6%;">&nbsp;</td>
			<td style="vertical-align:top;width:50.6%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:50.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Holder&#8217;s Address:&nbsp;&nbsp;&nbsp;&nbsp;<u>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp; </u></p>
			</td>
			<td style="vertical-align:top;width:50.6%;">&nbsp;</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>3
<FILENAME>ex_688393.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<html><head>
	<title>ex_688393.htm</title>

	<!-- Generated by ThunderDome Portal - 6/14/2024 12:39:56 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="margin: 0px 0pt; text-align: right; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 10.1</b></font></p>

<p style="margin: 0px 0pt; text-align: left; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>

<p style="text-align:center;font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><img alt="ex_688393img001.jpg" src="ex_688393img001.jpg" style="width:288;height:54;"></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">June 14, 2024</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">[&#9679;]</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 64pt;text-indent:-36pt;">Re: <u>Warrant Exercise Agreement</u> <u> </u></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">To Whom It May Concern:</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 27pt;">NovaBay Pharmaceuticals, Inc. (the &#8220;<u>Company</u>&#8221;) previously issued and delivered to you (&#8220;<u>Holder</u>&#8221; or &#8220;<u>you</u>&#8221; or &#8220;<u>your</u>&#8221;): (1) warrants issued in September 2022 (the &#8220;<u>September 2022 Warrants</u>&#8221;) to purchase Company common stock, par value $0.01 per share (&#8220;<u>Common Stock</u>&#8221;); (2) Series A-1 warrants issued in November 2022 (the &#8220;<u>Series A-1 Warrants</u>&#8221;) to purchase Common Stock; (3) Series B-1 warrants issued in May 2023 (the &#8220;<u>Series B-1 Warrants</u>&#8221;) to purchase Common Stock; and (4) Series B-2 warrants issued in May 2023 (the &#8220;<u>Series B-2 Warrants</u>&#8221;) to purchase Common Stock (collectively, the &#8220;<u>Warrants</u>&#8221;). The Warrants were issued pursuant to certain securities purchase and letter agreements, including the Securities Purchase Agreement, dated [&#9679;] (the &#8220;<u>Purchase Agreement</u>&#8221;).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">The Company is pleased to offer you the limited opportunity during the Exercise Period as provided herein to exercise your Warrants (the &#8220;<u>Limited Warrant Exercise Opportunity</u>&#8221;) at a reduced exercise price of $2.50 (the &#8220;<u>Reduced Exercise Price</u>&#8221;), as reduced from the current exercise price of the Warrants set forth under the column heading &#8220;Current Exercise Price&#8221; in <u>Annex B</u> to this letter agreement (the &#8220;<u>Current Exercise Price</u>&#8221;). Upon entering into this letter agreement, you have agreed to make a cash exercise of your Warrants at the Reduced Exercise Price for the number of underlying shares of Common Stock under the column heading &#8220;Exercise Amount&#8221; set forth on <u>Annex B</u> to this letter agreement (the &#8220;<u>Warrant Exercise</u>&#8221;). The &#8220;<u>Exercise Period</u>&#8221; is the period beginning on the date hereof through 8:00 a.m. New York City Time on June 14, 2024 (the &#8220;<u>Expiration Date</u>&#8221;). In connection with such Warrant Exercise, you will receive a New Warrant (as defined and provided below).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">The resale of the shares of Common Stock underlying the Warrants (&#8220;<u>Warrant Shares</u>&#8221;) have been registered pursuant to a registration statement set forth under the column heading &#8220;Registration Statement&#8221; in <u>Annex B</u> to this letter agreement (the &#8220;<u>Registration Statement</u>&#8221;). The Registration Statement is currently effective and, upon exercise of the Warrants pursuant to the terms hereof, will, to the Company&#8217;s knowledge, be effective with respect to the resale of the Warrant Shares. Capitalized terms not otherwise defined herein shall have the meanings set forth in the Purchase Agreement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">For the Warrant Exercise, if any, during the Exercise Period, the Company has agreed to allow you the limited opportunity to exercise your Warrants at the Reduced Exercise Price instead of the Current Exercise Price. You acknowledge that the ability to exercise your Warrants is a limited opportunity that expires at the end of the Exercise Period. Accordingly, you agree that any unexercised Warrant Shares underlying your Warrants after the end of the Exercise Period will continue to be exercisable at the Current Exercise Price on the terms set forth in your Warrants.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">Notwithstanding anything herein to the contrary, in the event that any Warrant Exercise would cause you to exceed the beneficial ownership limitations (&#8220;<u>Beneficial Ownership Limitation</u>&#8221;) set forth in Section 2(e) of your Warrants (or, if applicable and at your election, 9.99%), the Company shall only issue such number of Warrant Shares to you (as instructed in writing by you) that would not cause you to exceed the maximum number of Warrant Shares permitted thereunder, with the balance of Warrant Shares to be held in abeyance until you provide written notice to the Company that the balance (or portion thereof) may be issued in compliance with such Beneficial Ownership Limitations, which shall be deemed prepaid thereafter (including the payment in full of the exercise price), and exercised pursuant to a Notice of Exercise in the Warrants (provided no additional exercise price shall be due and payable).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">As an additional part of the consideration being provided by the Company for your completed Warrant Exercise, the Company shall also issue you or your designees within two (2) Trading Days after the Closing Date (as defined below), a new Series E Common Stock purchase warrant (the &#8220;<u>New Warrant</u>&#8221;), substantially in the form attached hereto as <u>Annex C</u>, to purchase up to a number of shares of Common Stock equal to <b>100%</b> of the number of Warrant Shares issued to you pursuant to your Warrant Exercise.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">The New Warrants:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">will be initially exercisable on the sixth month anniversary of the issuance date of the New Warrant;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">will have a term of exercise of five (5) years and six (6) months from the Closing Date; and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">will have an exercise price equal to $2.57.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">You may accept this offer and reflect your agreement with the terms of this letter agreement, including your acceptance of the New Warrants, by signing below.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 27pt;">Your acceptance and entering into this letter agreement shall constitute your notice and authorization to consummate the Warrant Exercise in the amount and for the aggregate exercise price as set forth on your signature page hereto on or before the Closing Date. By signing below, you represent that the Beneficial Ownership Limitation (as defined in your Warrants) will not be exceeded upon the issuance of all of the shares of Common Stock received from the Warrant Exercise or that you will comply with the abeyance process described above. The parties hereto acknowledge the Beneficial Ownership Limitation set forth in the undersigned&#8217;s Warrants, and, to the extent that the Warrant Exercise would exceed the Beneficial Ownership Limitation, then the Company shall only permit such exercise to the extent that such limitation is not exceeded as provided herein. Additionally, the Company agrees to make the representations and warranties to the Holder, and each of the Company and the Holder, as the case may be, will acknowledge and agree to the covenants set forth on <u>Annex A</u> attached hereto. Further, in connection with the issuance of the New Warrants as provided herein, the Holder agrees and shall make the representations and warranties as set forth in Section 3.2(a) through (g) of the Purchase Agreement to the Company, as the Company will be relying upon them in connection with the issuance of the New Warrants.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 27pt;">If this offer is accepted by your execution and delivery of this letter agreement, on or before the Expiration Date, then on or before 9:00 a.m. (New York City time) on June 14, 2024, the Company shall file a Current Report on Form 8-K with the U.S. Securities and Exchange Commission (the &#8220;<u>SEC</u>&#8221;) disclosing all material terms of the transactions contemplated herein, including forms of this letter agreement and the New Warrant as exhibits thereto (the &#8220;<u>8-K Filing</u>&#8221;). From and after the time of the 8-K Filing, the Company represents to the Holder that it shall have publicly disclosed all material, non-public information delivered to the Holder by the Company or any of its officers, directors, employees or agents in connection with the transactions contemplated by this letter agreement. In addition, effective upon the 8-K Filing, the Company acknowledges and agrees that any and all confidentiality or similar obligations under any agreement entered into in contemplation of the transactions contemplated by this letter agreement, whether written or oral, between the Company or any of its officers, directors, agents, employees or Affiliates on the one hand, and the Holder or any of its Affiliates on the other hand, shall terminate. From and after the 8-K Filing, the Company represents to the Holder that none of the Company&#8217;s directors, officers, employees or agents will provide the Holder with any material, nonpublic information that is not disclosed in the 8-K Filing.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">No later than the first (1st) Trading Day following the Expiration Date (the &#8220;<u>Closing Date</u>&#8221;), the closing shall occur at such location as the parties shall mutually agree. Unless otherwise directed by Ladenburg Thalmann &amp; Co. Inc. (the &#8220;<u>Placement Agent</u>&#8221;), settlement of the Warrant Shares representing the &#8220;Exercise Amount&#8221; set forth on <u>Annex B</u> to this letter agreement (the &#8220;<u>Exercise Amount</u>&#8221;) shall occur via &#8220;Delivery Versus Payment&#8221; (&#8220;DVP&#8221;) (i.e., on the Closing Date, the Company shall issue the Exercise Amount registered with your name and address, which shall be released by the Transfer Agent directly to the account(s) at the Placement Agent identified by you). Upon receipt of such Exercise Amount, the Placement Agent (or its clearing firm) shall: (i) promptly electronically deliver such Exercise Amount to the Holder, and (ii) pay the aggregate cash exercise price for the Exercise Amount on your behalf by wire transfer to the Company.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">Except as set forth herein, the terms of the Warrants, including but not limited to the obligations to deliver the underlying shares of Common Stock in connection with the Warrant Exercise, as may be adjusted, as provided herein, shall remain in effect as if the acceptance of the offer contained herein and entry into this letter agreement was a formal exercise notice under the applicable Warrant. If any Warrants have been fully exercised, then you agree to surrender such Warrants to the Company for cancellation pursuant to the terms of such Warrants.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">The Company acknowledges and agrees that the obligations of the Holder under this letter agreement are several and not joint with the obligations of any other holder of Warrants (each, an &#8220;<u>Other Holder</u>&#8221;), including the Other Holders who participate and enter into similar letter agreements as the Holder (the &#8220;<u>Other Warrant Exercise Agreement</u>&#8221;), and the Holder shall not be responsible in any way for the performance of the obligations of any Other Holder or under any such Other Warrant Exercise Agreement. Nothing contained in this letter agreement, and no action taken by the Holder pursuant hereto, shall be deemed to constitute the Holder and the Other Holders as a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Holder and the Other Holders are in any way acting in concert or as a group with respect to such obligations or the transactions contemplated by this letter agreement and the Company acknowledges that the Holder and the Other Holders are not acting in concert or as a group with respect to such obligations or the transactions contemplated by this letter agreement or any Other Warrant Exercise Agreement. The Company and the Holder confirm that the Holder has independently participated in the negotiation of the transactions contemplated hereby with the advice of its own counsel and advisors. The Holder shall be entitled to independently protect and enforce its rights, including, without limitation, the rights arising out of this letter agreement, and it shall not be necessary for any Other Holder to be joined as an additional party in any proceeding for such purpose.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">The Company hereby represents and warrants as of the date hereof and covenants and agrees from and after the date hereof until 180 days after the date hereof, that none of the terms offered to any Other Holder with respect to any Other Warrant Exercise Agreement (or any amendment, modification or waiver thereof) relating to any of the Warrants, is or will be more favorable to such Other Holder than those of the Holder and this letter agreement, unless such terms are concurrently offered to the Holder. If, and whenever on or after the date hereof until thirty (30) days after the date hereof, the Company enters into an Other Warrant Exercise Agreement relating to the Warrants, then (i) the Company shall provide notice thereof to the Holder promptly following the occurrence thereof (&#8220;<u>Notice of Transaction</u>&#8221;) and (ii) the terms and conditions of this letter agreement shall be, without any further action by the Holder or the Company, automatically amended and modified in an economically and legally equivalent manner such that the Holder shall receive the benefit of the more favorable terms and the obligation of the conditions (as the case may be) set forth in such Other Warrant Exercise Agreement (including, if applicable, the issuance of additional underlying shares of Common Stock), <i>provided</i> that upon written notice to the Company within five (5) days after receiving a Notice of Transaction, the Holder may provide written notice to the Company electing not to accept all of the benefits of any such amended and modified term and the related conditions, in which event the terms and conditions contained in this letter agreement shall apply to the Holder as it was in effect immediately prior to such amendment or modification as if such amendment or modification never occurred with respect to the Holder. The provisions of this paragraph shall apply similarly and equally to each such Other Warrant Exercise Agreement.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">Each party hereto shall pay the fees and expenses of its advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party incident to the negotiation, preparation, execution, delivery and performance of this letter agreement. The Company shall pay all transfer agent fees, stamp taxes and other taxes and duties levied in connection with the delivery of the Warrant Shares.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">Upon the countersignature and delivery of this letter agreement by the Holder, the parties will have mutually agreed to the consummation of the transactions set forth above, including the Warrant Exercise (as may be adjusted as provided herein), and the Company&#8217;s issuance of the New Warrants to you.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">No provision of this letter agreement may be waived, modified, supplemented or amended except in a written instrument signed, in the case of a waiver, by the party against whom enforcement of any such waived provision is sought, or, in the case of a modification, supplement, or amendment, by each of the parties hereto. No waiver of any default with respect to any provision, condition or requirement of this letter agreement shall be deemed to be a continuing waiver in the future or a waiver of any subsequent default or a waiver of any other provision, condition or requirement hereof, nor shall any delay or omission of any party to exercise any right hereunder in any manner impair the exercise of any such right.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">This letter agreement shall be governed by the laws of the State of New York without regard to the principles of conflicts of law thereof.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">***************</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">To accept this offer and to enter into this letter agreement, you must counter execute this letter agreement and return the fully executed letter agreement to the Company at email: jhall@novabay.com, attention: Justin Hall, on or before 8:00 a.m. (New York City time) by June 14, 2024.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">Please do not hesitate to call me if you have any questions.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:middle;width:48.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td colspan="2" style="vertical-align:middle;width:39.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Sincerely yours,</p>
			</td>
			<td style="vertical-align:middle;width:11.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:48.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:6.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:33.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:11.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:48.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td colspan="2" style="vertical-align:middle;width:39.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>NOVABAY PHARMACEUTICALS, INC.</b></p>
			</td>
			<td style="vertical-align:middle;width:11.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:48.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:6.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:33.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:11.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:48.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:6.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:33.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:11.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:48.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:6.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">By:</p>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:middle;width:33.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:11.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:48.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:6.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Name:</p>
			</td>
			<td style="vertical-align:middle;width:33.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Justin M. Hall</p>
			</td>
			<td style="vertical-align:middle;width:11.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:48.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:6.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Title:</p>
			</td>
			<td style="vertical-align:middle;width:33.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Chief Executive Officer and General Counsel</p>
			</td>
			<td style="vertical-align:middle;width:11.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 216pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Accepted and Agreed to:</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:top;width:38.4%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt;">Name of Holder:</p>
			</td>
			<td style="vertical-align:top;width:56.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">_____________________________________</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:38.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:56.5%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:38.4%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt;"><b><i><u>Signature of Authorized Signatory of Holder</u></i></b><b><u>:</u></b></p>
			</td>
			<td style="vertical-align:top;width:56.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">_____________________________________</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:38.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:56.5%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:38.4%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt;">Name of Authorized Signatory:</p>
			</td>
			<td style="vertical-align:top;width:56.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">_____________________________________</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 38.4%; padding-left: 9pt;">&nbsp;</td>
			<td style="vertical-align:top;width:56.5%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:38.4%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt;">Title of Authorized Signatory:</p>
			</td>
			<td style="vertical-align:top;width:56.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;_____________________________________</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:38.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:56.5%;">&nbsp;</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:top;width:70.5%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt;">Total Warrant Shares for all Warrants (<i>prior to the Warrant Exercise</i>):</p>
			</td>
			<td style="vertical-align:top;width:24.4%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">_________________</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 70.5%; padding-left: 27pt;">&nbsp;</td>
			<td style="vertical-align:top;width:24.4%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:70.5%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt;">Number of Warrant Shares being exercised under the Warrants contemporaneously with signing this letter agreement (as also set forth under the heading &#8220;Exercise Amount&#8221;&nbsp;in <u>Annex B</u>&nbsp;of this letter agreement):</p>
			</td>
			<td style="vertical-align:top;width:24.4%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">__________________</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:70.5%;">&nbsp;</td>
			<td style="vertical-align:top;width:24.4%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:70.5%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt;">Aggregate Exercise Price of the Warrants for the Exercise Amount:</p>
			</td>
			<td style="vertical-align:top;width:24.4%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">$_________________</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 70.5%; padding-left: 9pt;">&nbsp;</td>
			<td style="vertical-align:top;width:24.4%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:70.5%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt;">Number of Total Warrant Shares After the Warrant Exercise (as also set forth under the heading &#8220;Remaining Warrant Shares&#8221;&nbsp;in <u>Annex B</u>&nbsp;of this letter agreement):</p>
			</td>
			<td style="vertical-align:top;width:24.4%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">__________________</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><u>Annex A </u></b><u>&#8211;</u><b><u> Representations, Warranties and Covenants</u></b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><u>Representations, Warranties and Covenants</u>. The Company hereby makes the following representations and warranties to the Holder, and each of the Company and the Holder, as the case may be, acknowledge and agree to the covenants set forth below:</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">(a) <u>Registration Statement</u>. The Warrant Shares are registered for issuance on the Registration Statement and the Company knows of no reason as of the date hereof why the Registration Statement shall not remain available for the issuance and resale of such Warrant Shares for the foreseeable future. The Company shall use commercially reasonable efforts to keep the Registration Statement effective and available for use by the Holder until all remaining Warrant Shares underlying the Warrants are sold by the Holder.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">(b) <u>Authorization; Enforcement</u>. The Company will have the requisite corporate power and authority to enter into and to consummate the transactions contemplated by this letter agreement and otherwise to carry out its obligations hereunder and thereunder. The execution and delivery of this letter agreement by the Company and the consummation by the Company of the transactions contemplated hereby will be duly authorized by all necessary action on the part of the Company and no further action is required by the Company, its board of directors or its stockholders in connection therewith. This letter agreement has been duly executed by the Company and, when delivered in accordance with the terms hereof, will constitute the valid and binding obligation of the Company enforceable against the Company in accordance with its terms, except (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors&#8217; rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited by applicable law.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">(c) <u>No Conflicts</u>. The execution, delivery and performance of this letter agreement by the Company and the consummation by the Company of the transactions contemplated hereby do not and will not: (i) conflict with or violate any provision of the Company&#8217;s certificate of incorporation, bylaws or other organizational or charter documents; (ii) conflict with, or constitute a default (or an event that with notice or lapse of time or both would become a default) under, result in the creation of any Lien upon any of the properties or assets of the Company in connection with, or give to others any rights of termination, amendment, acceleration or cancellation (with or without notice, lapse of time or both) of, any material agreement, credit facility, debt or other material instrument (evidencing Company debt or otherwise) or other material understanding to which such Company is a party or by which any property or asset of the Company is bound or affected, other than for which a waiver has been obtained by the Company; or (iii) conflict with or result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or governmental authority to which the Company is subject (including federal and state securities laws and regulations), or by which any property or asset of the Company is bound or affected; except in the case of each of clauses (ii) and (iii), such as could not have reasonably be expected to result in a Material Adverse Effect.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">(d) <u>NYSE American Corporate Governance</u>. The transactions contemplated under this letter agreement comply with all applicable rules of the NYSE American LLC.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">(e) <u>Issuance of the New Warrants</u>. The issuance of the New Warrants in connection with the Warrant Exercise prior to the expiration of the Exercise Period as provided in this letter agreement shall be duly authorized and will be duly and validly issued, fully paid and nonassessable, free and clear of all liens imposed by the Company, and the shares issuable upon exercise of the New Warrants (the &#8220;<u>New Warrant Shares</u>&#8221;), when issued in accordance with the terms of the New Warrants, will be validly issued, fully paid and nonassessable, free and clear of all liens imposed by the Company. The Company shall reserve from its duly authorized capital stock a number of shares of Common Stock for issuance of the New Warrant Shares in full in accordance with its terms.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">(f) <u>Legends and Transfer Restrictions.</u></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 54pt;text-indent:36pt;">(i) The New Warrants and New Warrant Shares may only be disposed of in compliance with state and federal securities laws. In connection with any transfer of New Warrant or New Warrant Shares other than pursuant to an effective registration statement or Rule 144, to the Company or to an Affiliate of the undersigned or in connection with a pledge, the Company may require the transferor thereof to provide to the Company an opinion of counsel selected by the transferor and reasonably acceptable to the Company, the form and substance of which opinion shall be reasonably satisfactory to the Company, to the effect that such transfer does not require registration of such transferred New Warrant and New Warrant Shares under the Securities Act. As a condition of transfer, any such transferee shall agree in writing to be bound by the terms of this letter agreement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 54pt;text-indent:36pt;">(ii) The undersigned agrees to the imprinting, so long as is required by this Section (i), of a legend on any of the New Warrant and New Warrant Shares in the following form:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 72pt; text-indent: 0pt;">NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &#8220;<u>SECURITIES ACT</u>&#8221;), OR UNDER ANY STATE SECURITIES OR BLUE SKY LAWS. THE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE, AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. INVESTORS SHOULD BE AWARE THAT THEY MAY BE REQUIRED TO BEAR THE FINANCIAL RISKS OF THIS INVESTMENT FOR AN INDEFINITE PERIOD OF TIME. THE COMPANY MAY REQUIRE AN OPINION OF COUNSEL IN FORM AND SUBSTANCE REASONABLY SATISFACTORY TO THE COMPANY TO THE EFFECT THAT ANY PROPOSED TRANSFER IS IN COMPLIANCE WITH THE SECURITIES ACT. THIS SECURITY IS SUBJECT TO THE TRANSFER RESTRICTIONS SET FORTH HEREIN AND IN THE LETTER AGREEMENT, DATED JUNE 14, 2024, AS AMENDED FROM TIME TO TIME, COPIES OF WHICH ARE AVAILABLE WITH THE SECRETARY OF THE COMPANY. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT WITH A REGISTERED BROKER-DEALER OR OTHER LOAN WITH A FINANCIAL INSTITUTION THAT IS AN &#8220;ACCREDITED INVESTOR&#8221; AS DEFINED IN RULE 501(A) UNDER THE SECURITIES ACT OR OTHER LOAN SECURED BY SUCH SECURITIES.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 54pt;">The Company acknowledges and agrees that the undersigned may from time to time pledge pursuant to a bona fide margin agreement with a registered broker-dealer or grant a security interest in some or all of the New Warrants to a financial institution that is an &#8220;accredited investor&#8221; as defined in Rule 501(a) under the Securities Act and who agrees to be bound by the provisions of this letter agreement and, if required under the terms of such arrangement, the undersigned may transfer pledged or secured New Warrant to the pledgees or secured parties. Such a pledge or transfer would not be subject to approval of the Company and no legal opinion of legal counsel of the pledgee, secured party or pledgor shall be required in connection therewith. Further, no notice shall be required of such pledge. At the appropriate undersigned&#8217;s expense, the Company will execute and deliver such reasonable documentation as a pledgee or secured party of New Warrant may reasonably request in connection with a pledge or transfer of the New Warrant or New Warrant Shares.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 54pt;text-indent:36pt;">(iii) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Certificates evidencing the New Warrant Shares shall not contain any legend (including the legend set forth in Section (f)(ii) hereof), (i) while a registration statement covering the resale of such security is effective under the Securities Act, (ii) following any sale of such New Warrant Shares pursuant to Rule 144, (iii) if such New Warrant Shares are eligible for sale under Rule 144 without volume or manner-of-sale limitations pursuant to Rule 144, or (iv) if such legend is not required under applicable requirements of the Securities Act (including judicial interpretations and pronouncements issued by the staff of the Commission). The Company shall cause its counsel to issue a legal opinion to its transfer agent (if required by the transfer agent) and the undersigned (if requested by the undersigned) in connection with the removal of the legend hereunder. If all or any portion of a New Warrant is exercised at a time when there is an effective registration statement to cover the resale of the New Warrant Shares, or if such New Warrant Shares may be sold under Rule 144 or if such legend is not otherwise required under applicable requirements of the Securities Act (including judicial interpretations and pronouncements issued by the staff of the Commission) then such New Warrant Shares shall be issued free of all legends. The Company agrees that following such time as such legend is no longer required under this Section (f), it will, no later than the earlier of (i) one (1) Trading Day and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined below) following the delivery by a Holder to the Company or the Transfer Agent of a certificate representing Warrant Shares, as applicable, issued with a restrictive legend (such date, the &#8220;<u>Legend Removal Date</u>&#8221;), deliver or cause to be delivered to the undersigned a certificate representing such shares that is free from all restrictive and other legends. The Company may not make any notation on its records or give instructions to the transfer agent that enlarge the restrictions on transfer set forth in this Section (f). Certificates for New Warrant Shares subject to legend removal hereunder shall be transmitted by the transfer agent to the undersigned by crediting the account of the undersigned&#8217;s prime broker with the Depository Trust Company System as directed by the undersigned. &#8220;Standard Settlement Period&#8221; means the standard settlement period, expressed in a number of Trading Days, on the Company&#8217;s primary Trading Market with respect to the Common Stock as in effect on the date of delivery of a certificate representing Warrant Shares issued with a restrictive legend.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 54pt;text-indent:36pt;">(iv) In addition to such undersigned&#8217;s other available remedies, the Company shall pay to the undersigned, in cash, (i) as partial liquidated damages and not as a penalty, for each $1,000 of New Warrant Shares (based on the VWAP of the Common Stock on the date such Securities are submitted to the Transfer Agent) delivered for removal of the restrictive legend and subject to Section (f)(iii), $2.50 per Trading Day (increasing to $15 per Trading Day five (5) Trading Days after such damages have begun to accrue) for each Trading Day after the Legend Removal Date until such certificate is delivered without a legend and (ii) if the Company fails to (a) issue and deliver (or cause to be delivered) to the undersigned by the Legend Removal Date a certificate representing the Securities so delivered to the Company by such undersigned that is free from all restrictive and other legends and (b) if after the Legend Removal Date such undersigned purchases (in an open market transaction or otherwise) shares of Common Stock to deliver in satisfaction of a sale by such undersigned of all or any portion of the number of shares of Common Stock, or a sale of a number of shares of Common Stock equal to all or any portion of the number of shares of Common Stock that such undersigned anticipated receiving from the Company without any restrictive legend, then, an amount equal to the excess of such undersigned&#8217;s total purchase price (including brokerage commissions and other out-of-pocket expenses, if any) for the shares of Common Stock so purchased (including brokerage commissions and other out-of-pocket expenses, if any) (the &#8220;<u>Buy-In Price</u>&#8221;) over the product of (A) such number of New Warrant Shares that the Company was required to deliver to such undersigned by the Legend Removal Date multiplied by (B) the lowest closing sale price of the Common Stock on any Trading Day during the period commencing on the date of the delivery by such undersigned to the Company of the applicable New Warrant Shares (as the case may be) and ending on the date of such delivery and payment under this clause (ii).</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">(g) <u>Listing of Common Stock</u>. The Company shall, subject to applicable requirements of the NYSE American, apply to list or quote all of the New Warrant Shares on the NYSE American and promptly secure the listing of all of the New Warrant Shares on such NYSE American.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">(h) <u>Registration Statement</u>. On or prior to ninety (90) days after the Closing Date, the Company shall prepare and file a registration statement with the SEC covering the resale of 100% of the Common Stock underlying the New Warrants issued to the Holder and the Other Holders. The Company will use its best efforts to cause the registration statement to be declared effective by the SEC and to keep such registration statement effective at all times until no Holder owns any New Warrants or New Warrant Shares issuable upon exercise thereof.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><u>Annex B </u></b><u>&#8211;</u><b><u> Warrant Amounts</u></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:82%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align: top; width: 16%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 14%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><u>Total </u></b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><u>Warrant </u></b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><u>Shares</u></b><sup style="vertical-align:top;line-height:120%;">(1)</sup></p>
			</td>
			<td style="vertical-align: bottom; width: 14%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><u>Current </u></b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><u>Exercise </u></b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><u>Price</u></b></p>
			</td>
			<td style="vertical-align: bottom; width: 16%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><u>Exercise </u></b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><u>Amount</u></b></p>
			</td>
			<td style="vertical-align: top; width: 16%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><u>Remaining </u></b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><u>Warrant </u></b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><u>Shares</u></b><sup style="vertical-align:top;line-height:120%;">(2)</sup></p>
			</td>
			<td style="vertical-align: top; width: 23%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><u>Registration </u></b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><u>Statement No.</u></b></p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: top; width: 16%;">&nbsp;</td>
			<td style="vertical-align: top; width: 14%;">&nbsp;</td>
			<td style="vertical-align: top; width: 14%;">&nbsp;</td>
			<td colspan="2" style="vertical-align: top; width: 16%;">&nbsp;</td>
			<td style="vertical-align: middle; width: 23%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: top; width: 16%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>September 2022</b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Warrants</b></p>
			</td>
			<td style="vertical-align: top; width: 14%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;_______</p>
			</td>
			<td style="vertical-align: top; width: 14%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;$___</p>
			</td>
			<td style="vertical-align: top; width: 16%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;__________</p>
			</td>
			<td style="vertical-align: top; width: 16%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">_______</p>
			</td>
			<td style="vertical-align: middle; width: 23%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">333-269083</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: top; width: 16%;">&nbsp;</td>
			<td style="vertical-align: top; width: 14%;">&nbsp;</td>
			<td style="vertical-align: top; width: 14%;">&nbsp;</td>
			<td colspan="2" style="vertical-align: top; width: 16%;">&nbsp;</td>
			<td style="vertical-align: middle; width: 23%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: top; width: 16%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Series A-1</b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Warrants</b></p>
			</td>
			<td style="vertical-align: top; width: 14%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;_______</p>
			</td>
			<td style="vertical-align: top; width: 14%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;$___</p>
			</td>
			<td style="vertical-align: top; width: 16%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;__________</p>
			</td>
			<td style="vertical-align: top; width: 16%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">_______</p>
			</td>
			<td style="vertical-align: middle; width: 23%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">333-268738</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: top; width: 16%;">&nbsp;</td>
			<td style="vertical-align: top; width: 14%;">&nbsp;</td>
			<td style="vertical-align: top; width: 14%;">&nbsp;</td>
			<td colspan="2" style="vertical-align: top; width: 16%;">&nbsp;</td>
			<td style="vertical-align: middle; width: 23%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: top; width: 16%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Series B-1</b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Warrants</b></p>
			</td>
			<td style="vertical-align: top; width: 14%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;_______</p>
			</td>
			<td style="vertical-align: top; width: 14%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;$___</p>
			</td>
			<td style="vertical-align: top; width: 16%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;__________</p>
			</td>
			<td style="vertical-align: top; width: 16%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">_______</p>
			</td>
			<td style="vertical-align: middle; width: 23%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">333-272304</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: top; width: 16%;">&nbsp;</td>
			<td style="vertical-align: top; width: 14%;">&nbsp;</td>
			<td style="vertical-align: top; width: 14%;">&nbsp;</td>
			<td colspan="2" style="vertical-align: top; width: 16%;">&nbsp;</td>
			<td style="vertical-align: middle; width: 23%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: top; width: 16%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Series B-2</b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Warrants</b></p>
			</td>
			<td style="vertical-align: top; width: 14%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;_______</p>
			</td>
			<td style="vertical-align: top; width: 14%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;$___</p>
			</td>
			<td style="vertical-align: top; width: 16%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;__________</p>
			</td>
			<td style="vertical-align: top; width: 16%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">_______</p>
			</td>
			<td style="vertical-align: middle; width: 23%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">333-272304</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 16%;">&nbsp;</td>
			<td style="vertical-align: top; width: 14%;">&nbsp;</td>
			<td style="vertical-align: top; width: 14%;">&nbsp;</td>
			<td style="vertical-align: top; width: 16%;">&nbsp;</td>
			<td style="vertical-align: top; width: 16%;">&nbsp;</td>
			<td style="vertical-align: middle; width: 23%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: top; width: 16%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;TOTAL</b></p>
			</td>
			<td style="vertical-align: top; width: 14%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>&nbsp;_______</b></p>
			</td>
			<td style="vertical-align: top; width: 14%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align: top; width: 16%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>&nbsp;</b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>&nbsp;__________</b></p>
			</td>
			<td style="vertical-align: bottom; width: 16%;"><b>&nbsp;__________</b></td>
			<td style="vertical-align: top; width: 23%;">&nbsp;</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(1)</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Represents the total number of Warrant Shares underlying each series of Warrants held by the Holder as of the date hereof and prior to the completion of the Warrant Exercise.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(2)</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Represents the remaining Warrant Shares underlying each series of Warrants held by the Holder immediately after the completion of the Warrant Exercise.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>nby-20240614.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 6/14/2024 12:34:26 PM-->
<xsd:schema xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:nby="http://www.nby.com/20240614" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.nby.com/20240614">
<xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
<xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/stpr/2023" schemaLocation="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"/>
<xsd:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
<xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/sic/2023" schemaLocation="https://xbrl.sec.gov/sic/2023/sic-2023.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/currency/2023" schemaLocation="https://xbrl.sec.gov/currency/2023/currency-2023.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/exch/2023" schemaLocation="https://xbrl.sec.gov/exch/2023/exch-2023.xsd"/>

<xsd:annotation>
<xsd:appinfo>
<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nby-20240614_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nby-20240614_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nby-20240614_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
<link:roleType id="statement-document-and-entity-information" roleURI="http://www.nby.com/20240614/role/statement-document-and-entity-information">
<link:definition xmlns="http://www.xbrl.org/2003/linkbase">000 - Document - Document And Entity Information</link:definition>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:presentationLink</link:usedOn>
</link:roleType>
</xsd:appinfo>
</xsd:annotation>
<xsd:element abstract="true" id="nby_DocumentAndEntityInformation" name="DocumentAndEntityInformation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>5
<FILENAME>nby-20240614_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 6/14/2024 12:34:26 PM-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
<link:roleRef roleURI="http://www.nby.com/20240614/role/statement-document-and-entity-information" xlink:href="nby-20240614.xsd#statement-document-and-entity-information" xlink:type="simple"/>
<link:definitionLink xlink:role="http://www.nby.com/20240614/role/statement-document-and-entity-information" xlink:type="extended">
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
<link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
<link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>

<link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>


<link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" xlink:type="arc"/>
<link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
<link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
<link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
<link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
<link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" xlink:type="arc"/>
<link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" xlink:type="arc"/>
<link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
<link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
<link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:type="arc"/>
<link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:type="arc"/>
<link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" xlink:type="arc"/>
<link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" xlink:type="arc"/>
<link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_WrittenCommunications" xlink:type="arc"/>
<link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SolicitingMaterial" xlink:type="arc"/>
<link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementTenderOffer" xlink:type="arc"/>
<link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementIssuerTenderOffer" xlink:type="arc"/>
<link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" xlink:type="arc"/>
<link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
<link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" xlink:type="arc"/>
<link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
<link:definitionArc order="21" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
<link:definitionArc order="22" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>

</link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>nby-20240614_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 6/14/2024 12:34:26 PM-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple"/>
<link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
<link:label xlink:label="dei_EntityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
<link:label xlink:label="dei_LegalEntityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentInformationLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentInformationTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentType-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document, Type</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentPeriodEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document, Period End Date</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
<link:label xlink:label="dei_EntityRegistrantName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Registrant Name</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
<link:label xlink:label="dei_EntityIncorporationStateCountryCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Incorporation, State or Country Code</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
<link:label xlink:label="dei_EntityFileNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, File Number</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
<link:label xlink:label="dei_EntityTaxIdentificationNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Tax Identification Number</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressAddressLine1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, Address Line One</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressCityOrTown-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, City or Town</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressStateOrProvince-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, State or Province</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressPostalZipCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, Postal Zip Code</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
<link:label xlink:label="dei_CityAreaCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
<link:label xlink:label="dei_LocalPhoneNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xlink:type="locator"/>
<link:label xlink:label="dei_WrittenCommunications-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xlink:type="locator"/>
<link:label xlink:label="dei_SolicitingMaterial-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xlink:type="locator"/>
<link:label xlink:label="dei_PreCommencementTenderOffer-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:type="locator"/>
<link:label xlink:label="dei_PreCommencementIssuerTenderOffer-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
<link:label xlink:label="dei_Security12bTitle-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
<link:label xlink:label="dei_TradingSymbol-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
<link:label xlink:label="dei_SecurityExchangeName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
<link:label xlink:label="dei_EntityEmergingGrowthCompany-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Emerging Growth Company</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
<link:label xlink:label="dei_AmendmentFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
<link:label xlink:label="dei_EntityCentralIndexKey-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Central Index Key</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey-label" xlink:type="arc"/>

</link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>nby-20240614_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 6/14/2024 12:34:26 PM-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:roleRef roleURI="http://www.nby.com/20240614/role/statement-document-and-entity-information" xlink:href="nby-20240614.xsd#statement-document-and-entity-information" xlink:type="simple"/>
<link:presentationLink xlink:role="http://www.nby.com/20240614/role/statement-document-and-entity-information" xlink:type="extended">
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
<link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>

<link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>

<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" xlink:type="arc"/>
<link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
<link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
<link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" xlink:type="arc"/>
<link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" xlink:type="arc"/>
<link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
<link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
<link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:type="arc"/>
<link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:type="arc"/>
<link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" xlink:type="arc"/>
<link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" xlink:type="arc"/>
<link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_WrittenCommunications" xlink:type="arc"/>
<link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SolicitingMaterial" xlink:type="arc"/>
<link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementTenderOffer" xlink:type="arc"/>
<link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementIssuerTenderOffer" xlink:type="arc"/>
<link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" xlink:type="arc"/>
<link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
<link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" xlink:type="arc"/>
<link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
<link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
<link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>

</link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>ex_688393img001.jpg
<TEXT>
begin 644 ex_688393img001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  V 2 # 2(  A$! Q$!_\0
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M#&/4YJHQON3*5MCBOC)_R/*?]><?_H3UPUG97.H3M!:1&641M)L7J549./?
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M\?K7;V'P2OKJVBFN=7M8O,4,5CA,F,^^1FN0\8>';7PMK2Z9;:A]M98@TS;
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MB^)7B#S(;1YF7Y8XHO\ 56Z^['@>Y/7]*[W3OA'=Z:^?M.C7F#D&[L7<_D)
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MKI7AZRT9HGMFF+16XMP9'W$KN+9/JQ)/-)=>&M,O6OVNH!-)>C;([@%D&W:
MAQ\N.OU)-%%+F=[ARK8LW^E6VJ:/+I=X9)+>:+RI#NPS#UR.]<6WP:\+$Y#7
MZCT%Q_\ 6HHJXSE'9DRIQENCIO#WA/1O"T4B:7:['DQYDKL6=\=,D]O:MVBB
..H;;=V6HJ*L@HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140345279548800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th"><div>Jun. 14, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity, Registrant Name</a></td>
<td class="text">NovaBay Pharmaceuticals, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document, Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document, Period End Date</a></td>
<td class="text">Jun. 14,  2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity, Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity, File Number</a></td>
<td class="text">001-33678<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity, Tax Identification Number</a></td>
<td class="text">68-0454536<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity, Address, Address Line One</a></td>
<td class="text">2000 Powell Street, Suite 1150<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity, Address, City or Town</a></td>
<td class="text">Emeryville<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity, Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity, Address, Postal Zip Code</a></td>
<td class="text">94608<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">510<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">899-8800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">NBY<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity, Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity, Central Index Key</a></td>
<td class="text">0001389545<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>11
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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ME!HE,1MI$.GU^]>]7H 2576!XF[^10MKN83 I&DN#QYB:JEPH144333-JW)
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M+6XWG($GN ;P^THI>WQPY]ORWQ.C_P!02P,$%     @ ^T7.6)^@&_"Q @
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M\SR. !9GD*88 J<11S &P %#TG1X#SY['R73>RHY_U=3_ 102P,$%     @
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M-4H2U\7!ZQ^4ZD2HN7/08&<B+EA0BJN$7/D=<.I[.T!*1D.QD8E>I6.5Z*U
M.EK >MKBRAE#VQH%.JB]XY8:8P*IL0,@9^O1=#%-)IXPC,^[V?S!9@K(RDT*
M$3FQ!'_'G2/)W55D(TADIJ]X(;+U[/M!3EN#OI'-X_T,:3?D@6)8YL_X>\87
M_QO.\1'"[K\_L;S63AI_YHOA/UY_ 5!+ 0(4 Q0    ( /M%SE@'04UB@0
M +$    0              "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#
M%     @ ^T7.6$5]ZW?O    *P(  !$              ( !KP   &1O8U!R
M;W!S+V-O<F4N>&UL4$L! A0#%     @ ^T7.6)E<G",0!@  G"<  !,
M         ( !S0$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " #[
M1<Y8 61H3$X$  "J$   &               @($."   >&PO=V]R:W-H965T
M<R]S:&5E=#$N>&UL4$L! A0#%     @ ^T7.6)^@&_"Q @  X@P   T
M         ( !D@P  'AL+W-T>6QE<RYX;6Q02P$"% ,4    " #[1<Y8EXJ[
M',     3 @  "P              @ %N#P  7W)E;',O+G)E;'-02P$"% ,4
M    " #[1<Y8.JJBYT !   \ @  #P              @ %7$   >&PO=V]R
M:V)O;VLN>&UL4$L! A0#%     @ ^T7.6"0>FZ*M    ^ $  !H
M     ( !Q!$  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%
M  @ ^T7.6&60>9(9 0  SP,  !,              ( !J1(  %M#;VYT96YT
A7U1Y<&5S72YX;6Q02P4&      D "0 ^ @  \Q,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1.1.u2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="nby20240614_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nby.com/20240614/role/statement-document-and-entity-information</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>nby-20240614.xsd</File>
    <File>nby-20240614_def.xml</File>
    <File>nby-20240614_lab.xml</File>
    <File>nby-20240614_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" original="nby20240614_8k.htm">nby20240614_8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>17
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "nby20240614_8k.htm": {
   "nsprefix": "nby",
   "nsuri": "http://www.nby.com/20240614",
   "dts": {
    "schema": {
     "local": [
      "nby-20240614.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/currency/2023/currency-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/exch/2023/exch-2023.xsd",
      "https://xbrl.sec.gov/sic/2023/sic-2023.xsd",
      "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "nby-20240614_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "nby-20240614_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "nby-20240614_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "nby20240614_8k.htm"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 26,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 22
   },
   "report": {
    "R1": {
     "role": "http://www.nby.com/20240614/role/statement-document-and-entity-information",
     "longName": "000 - Document - Document And Entity Information",
     "shortName": "Document And Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "d20248K",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nby20240614_8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d20248K",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nby20240614_8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.nby.com/20240614/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.nby.com/20240614/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://www.nby.com/20240614/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationTable",
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.nby.com/20240614/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document, Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.nby.com/20240614/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document, Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.nby.com/20240614/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.nby.com/20240614/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.nby.com/20240614/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.nby.com/20240614/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.nby.com/20240614/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityDomain",
     "presentation": [
      "http://www.nby.com/20240614/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.nby.com/20240614/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.nby.com/20240614/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.nby.com/20240614/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.nby.com/20240614/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.nby.com/20240614/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://www.nby.com/20240614/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.nby.com/20240614/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.nby.com/20240614/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.nby.com/20240614/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.nby.com/20240614/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.nby.com/20240614/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.nby.com/20240614/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.nby.com/20240614/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.nby.com/20240614/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>18
<FILENAME>0001437749-24-020277-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001437749-24-020277-xbrl.zip
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M<G0ZW#TXQ(7&!8-GAH>C$'^'_^WM'9_N'QS]=/AK&+P>XK:=P]+#=%[2JL,
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M\ES.)1W;"'WK:6S%[9,!Z_Y #C1N N9U: *K4/ F=0%A-7!Y2C$4.Q HL)C
M0 4C)S*Y;M+^[GKIA:BEDQ^"1],.&D):/JP.3 096><NX6J(8]O-(HDX8N.R
M@-LBB8DG&*@@[V'?KBJW:1(3>^BVK*W<8"M]Q@C1DEEP&;D0-C5?(VA&S%(Q
M4=*^.X#,1@+66V%!JVP%+]%2]#Z"-C3D@AJQ00YRQ@@#([-*^UF%&?UEATUQ
M>-$4!':C[D'??($).76=S.9U$CO.EH[E86+-+1,O,4?N>5U"I!%NXPA#28WE
M*##B9D)5[1FK!+N'=UV3$_J(6)%S(-DVZ0 2B164#=DNVRC1GYD+E@\&L*!N
MHQV6Q*408F?9O/$#@C+BY969R,H#*0BTMZ5E6;V&2LTQ-LZ9<HRRU;&H*H(/
ML]'">!+D6=,JFV;E6M:DRSZQQ18\-&GB"2ZI T -YR"+K@4] U>6XE_D&@BU
MN\]X]1 J.TXFF%*$8V8?U03-<50*C=RU>?P=-?@;A3>1KQ..SK3+K.98Y*9&
M@).3I\YY![&VY+Q9[,JZ&FQAB)17RGO3H$.W3"3_%BQRCV[0(O?HSB)W9Y%;
MI5;V:I5'1?"R9(T [EN18X"/G4W*=,X:(CPR-8]4^A&L/# WF+'(NIO/Z1M,
M! U= :(K89=<***(JN;LN,R&(L(2C14NX4(6Z5NZJ9ITV0M)SLE8AM6"(MZZ
MDOQK07ZY=R*USL"+>NCM@(/\I'I&5 $KZL'/-8=[#4]<8,GSL->" D4+<_N8
M^>T["+T6N3U8Q0MD N?1>_$(CR1@52PE5E12:U:PP"-K^6%"+7I2E'*6TWD(
M.%B;K21U]%Z; U <(?LK87'2*%KD+SM.JL6G&BJP4SDS>EXZ$+<O_C8T(!9=
MLS5)VG5W()$<.OZVI)\4B2S)S#&(*9-Z_7B?9P'LE8K1P(T)\8/+XCJYXLHS
M8:"ROHG-7&GG;XO#F55=,XU(AFEB.=HG%KI>@FNT8&@G@AC@FPH=&K1P::US
M/B343&(E+SN I D_D+&D=W%^'LQU,ZR\J4"TF6A)/F30"E-4!Q_B2A*BFQ<,
MG0PG$A2I B:;%(O*#HH!MKR8!23<3%*Q\H'X/AN#W)F@V*WHW2%SB[JEQ[:8
M36*Y6>;;$2F>7 NXE',!&[09$P12,4FJ2H"/.F!/"1X FIU*S !.M3.VDG(<
M<B8(T&Q GT@KW)])ED0$J6,7SA%]@-0Y"<+7R0Z#CB'315,6.:@3JQQ*J*Q$
M!E^XD'NTIO0#I>W<OGO@6Q#JO[]!H?[[.Z'^3JA?+<OT"S-9H;C@;E&\JYIA
M\>2[0Z,DHTBAS%NA:4$",\?X%H=9,WHUR;%+"7P6B0).PQ4E%BFW.%],K7)]
M^)69(NZ2?;Y8#DWR%27[F(J&S]EGM?/#,_G+@ X'AR;^ORL!!8^:A,[AA]W'
MA,239EF$I@QGF>*7KN>BZ]1I?ZGC=O1%"<Y7)K^GF+UEW$IOU6H'/V37_3 %
MU(HUJEPX\>0;=7&1D)REO;V>T7<(EVV&AO,JU+#S+)F=)&6%O@?4ISER,PKP
M.D-MN;W10,32]MP<TY-$UTL'=CSGL*[+=,Q0C2>,0F7[-1'+6*#*\@2%8RIA
M45R310#=@Y6.\]G53P3'U\!=J\MT;I&4@XU!]40&[%K1\?4Z];Q,+@K;F>"C
MVW=8D_TAMJH5>$.TS%E'$:'Y/%FOOS6AV]J#_]D7+ZFXO$"IPLGBZD18+)-'
M!>N\_JBX^0Y\.0PO\.WM'!!,+@.4MW0X6L=97+W,AB:[%EO'_INQD'H&3+.R
M')<+:S2$5I[S,[4[.G. +-!6UW=C^<<['".Z#6<Q1]I="IJ/$^5O7@X8:4R/
MW68E>905%ZAK-NK"DC8:V=4</WU=L306YC"[+"Q5:*^^CRY4U2"LX^> I&&<
MOAD5C8E/M;8%P 4W04Q=L3MTX-/M/-B(M=\0AG@9Y1<)8M-I1;]<9#HA6X'T
M5@Y";VTYOM):#HH%E^<O5B/40. &'$.O[WY6X/-J6G(J*1P 7<@?,S439E,5
M&8J6R I@=CI7CRY7M);0&GCQ"\# &VM+2X&C@ NZ>>5UDEF:-_=7 7H(%(?#
MCLCBEH@-R4:7U.YSXBL;9-"3Q<*<QL9);"%E]S[#%6@A9T9*TH:_+G[DC<?8
MEE==2,8 R"<$]R>(TVI2)FVA%FI#J>Q:I?A4:[Z/'_P@F;C-&]H"5O@6%M\U
M[OA%L5?L1]AG]LL+.SX!&KQ"=7@I]P8%E)&<-H&91Y.E-B4[J^J$";(SW%[S
M2'ML6.C"@)H%&7G%<LB,CL/SK"W6<!HWR *_]%*QU=QI%-C?&,3)>NG8A7VD
M4)&[RX2X;0OG7$M4M$S7) 5SN2X[[-W$4"32NHCJ1D 2@SC1L97LU"$WN7J]
MQR=;1=7&79GF>A&;%;)6#R$T"A-Z%4J\+!J36F,F%#@Q->@MDL?>"->PT6DX
M)2N=L)"1HW^/46CD!M);MZ=C"D,%Q$)GG?T@(4>L0=.4HLU-+X :)]AJL8!]
M(I.[ZZ.AS/8]_STOR*?Y2MT,SL4D,_+@DN2SEKQL+:AD$.-KJO.6A(NV5$VO
M!IF=4JC.7%&28$<Z2$[MMTD@:P7 P;B<41^P4<L4[/L@<FGC9!UZ,^UVNZB+
MX^V2OMV*WK9:WQ!P6U6S5 644>QR9"/OD$_N0V9[;0%XL8'#"NOM9TN67LRV
M*KUR#[>>//FKFG3;!JJ3TT9U3B1=S\([;M)/T4CM(#N)>&,?F7?B?!2D&84Q
M4WYNPD&<\OLZ++VE!)[+/-V$]76:3',J>D6N416I_.26[$2_2> RR;I<GBO6
M2>' %*C +&B/4(1?;@7#?"EVK;8M$A%WU9*2.9T:!%Z6>>GG.KW<2; P$ @J
M"ZYM+!_2OY1/-7 KIA;J]SO BV,W45L%@?85!#UO7UE=A-'2:.'[NE1R0XI!
MOS,N)4V.=7$<F#@=!94 +Z5 (<CMT7=:+[M ^IW=I/C?LB3:<@>T(9JA$KS9
MP3 0OJ>B#A*U1!2B@&-'4!1E="):15T?C]6JI1<KA-$7N0K/#%'565SE<*G%
M7)8$].D$[7^8@TVD5J6E"E2%M0:)(N.*DK[AU6BGO#$V[$Q37?7WB*F3;# $
MRE=5A4V$S?R^KP7)ZEMP,/]P@P[F'^X<S'\<!_,'^)01I$(5QB W5I>#N?__
MZ'Y.2D+A&.I(R<H Y-TFUG'K8(FCOFJG+"'MIY1-$;/-XVR>I>W9PZ$J3LP)
MZPS*:@JC4OSAOL(/A=L1+R#/0F6)>%R8;TX 1!PIP(4\DSQVO(ET[^$S,0*]
M*8T$KSGK[RI@*Z((@&B5=T7+TI*3)$&CT+]9J5B6YJ225M*\2[3<(!% D)VO
MBC16HFA<+,9U:#E;E3=+]-0NC2'Q8R;%5_3>]Q59J^I,S63SB5J'^8*..X>0
M;*UX.X/1*KX7<>R043Q.QO#8HFSHD:K"76_3!':MMQ2:5R_CG924*!U6;&TA
M#U2U&//3U3K:(R'31D&&$;%E0[\(I5#;I)B-L0:YDY6)RR,%R7'PB5!?A80_
M^("^JQFB(S0[YSIQ5P/>THJ+D-/]P<@/8KWMT81<,IE$\Q0C&WF8OD)/1@C'
MV%LWX[U-/+$3&1XY$?$F$AYFE)1175B@;&L91#;8/TK6!=0V%N52;XC*>NW2
M\B2/F@/J29-TS-[L%<D+,HM^\,#Z54O3IS'G-II<T\=L(J!!\&:-0;I2I=RX
MJ+)2K3L!X-H;9A<QZ&&L",2LX5D)!!0PWFE!Q?I4>HB$G6=TN^:Z:$,/6Z4M
M[NSR8K1?5Y:=>LVFS??420/E3A@"6SCY)&LP\)+P3;>?/'//U9U \&DE[\\6
MXPKMK$ ZC"(2',,F85QRU8GN8(BO'1"$:(Y<-<P$+!G"OE$NR&(1*J99$.YY
M5M'#79$ 1 D\3CLS1VX5N01)H#;V4)40P8IQ33'>6'4O4J8*P8^\%!AUN<B(
MSOI87^T8,$_46 P82PM @0U[XJ4911,)J-<)3FR\L.*?E!;O]15Z?,7[NIGP
M-#$IW-)K["578S8W6<K68K;<B.&5Y'=*ZNX4+1"D)! $AUS&BK)L<X3-<]D"
M8]NRVP))UK!R#=IN(,WU"I54'RF:0"18D$9S#5-PP5*6,4.6@0(1;M^:@H%.
M<MDZK]W0=&[;UMNILFOU=1J*Y45H&>_*P08;:R7&M$;[M3C838:U56E @H!;
MNI>X*7$WILYY81.S<NRM=&;[Q\V(Y7YJGSNRME$97$Z:[ 8!P+3$Y:@U[78,
MVJ[4U3T-3/)4_XBT_$'G%==WG"R)-A4-R"I8R)G(BXDL<6?)F8@*E&R8) [Q
M=G#<SJ=NR2VL^/@MF/P>WZ#)[_&=R>^/8_+[6%%STB=JGH#8=8IBU[YMQV$I
M<Y^KRVOFU(#.=4U)#>PP9H(Q*MVEP.M+1=J&B<E39=AV!/N>X 7HB)<B&UD/
MD-=HY8T<.A:'>E'FME+OF+K6B8WUQ\LHU)4R<_EQ9Z$1=/';.4M39D217A)H
M9(Z1$]-IV+!7A!8*.RCVN D7Y'H**6"2TUFMCZV12-ZBA5$V<"&\[/UWY61;
M53!JHUO,P8YAP(O>!+Y)_&@7RORJB]\>EA)Q,,FR0\ZQ@9"LYB16#(LAW4G4
M1J)MEZ@;Z_Z[R\MF)R7,H4D:GT5*_I\UY&.GUULB'?N'Q)>-961=(G*/.;Q-
M0N[I;6#"-DQ\;/.EU=(Q#]6KL7,G+-]N02/N$S1>@L 8S1@<X-S<0LK#Y5XS
M*]U6(;FM' L\(TYD2P[]4'_1181AB"A^<# E1RU;-V$E-E"V<LT2\F5P='!5
M9%@WP8I^-XFVF TGM?D4E #GDX6FCL?*T=D]HQD@!)&2+LLLG2"8!Y*VPI((
M-=I"R"Z?I;)V:!F*X Y4)#[A+:+]%E>MYCP:@0ZQQ"NS/A')OXD4<&PNDW+G
M6!.RIQ-:T'E3&F2MT+>GO*")BO/F3S941'\SE-5=4*JKHFY;%_R,KQKK?FG<
M*E*$BKDG&C/-N*P106^IAF6;MDIP!!)46"9+Y'6Z3 U72S2N0VM(C[;_JLE/
MJ,CVA+A2*KFLO@AA-Z5)D#:\ZI[P#$O$^K.V",%27)2S^2*K"N5=,HO9W*!&
M&VEE' ^9=G=2F%-=V#L3K[D;7!OT<ZX='O_%;$;IHI$1[7FNFM1U'4YS#L>+
M"KV=E>,M6:E4>+L1-O:"-8--T@P,DVH5_ <JE<4^1?@T)W+ PRJU]AKORK'(
M-NU/B\95\5)1?!]1=).2._V1$0F;HFQTW 2N85XL[BQV:6](=WIU0W1J \>A
MPDQ6_1\7*;H32-5(_"ZDJXOXF18:OI5<<65B0SAU3#KL0[-=K3X@'3OQDT4_
M"MM@S<QA&8:))\0C3V3@8^,4I7<QDE"6ZG)MU:*\XI!AZRV3YZV\6!&%\%8@
MO4N[MB-GF(%&@/Y;Z,-Z1I<UY(VE76J35SN6GCWO=J#D&@MCH(#[LM!:":-W
M+)]_IYL).EJ%<8'R&GEV?8$+6 ZY@"EYSG05=:WGV;%E@5,^R\#%=CVN3Y\+
MDH:LNVHMYZPTHN[CUIHG!H,7?:5E\C!,T1$ZAYD3U4GEY$0%14O2D:X"0GF)
MP%A,46HR)*$LA,P-[U.866XJA73T1Q%A?2(/!AE+"LQE05/0"=>] @TKX+J
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MA(PN\=0&C[8"1>[!FNY*!U6R ^6.33"1&#0YG](V=5AVC<^28-L^C-O'@^\
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M0(IZJZ8I1$Z\*>UEU&22Q(+=SZX&MGD]+R0FB:4[>W$]XW\.*T/]5D0%#E"
M)XO<OC/Y31B'[]^D<?C^G7'XSCC\2<;APZ*">8-,.P7E9!^5J\5$.5M?(R:9
MEMOL2!''6#(I@#<9X599>Y(4ANJ#L4\UT$P?YHZIU9#1\&H>7NP.;^8,KZV
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M $&!&=O(W;B1Y.)H8A&0%('6J73:;VLS?<,C! 7'5S87O.AIG!$3=;/6%,P
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M;CIYS#*^'0[/SC>-[:_5'_=9_6S*9@>_8-T-6,W+>I:]^/]02P,$%     @
M^T7.6"W Y0?>+   %!$!  T   !E>%\V.#@S.3,N:'1M[7W[<]M&TN#/F[]B
MSIO-1UU1C!ZV8UN*ZRB)MKF1)1U))>>ZNOH*)(<B8A!@\)#,_>NO'_,$0$I6
M+%FRF=JU31*8Z>GI=_?T[$_S6?1Z?RJ#\>L?_K&?AWDD7\M/__W\Q8O=E[LM
M^'7_9_[RAW_ [_]C<U.\E;%,@UR.Q7 A!M,B'LOT*)E)<9:D>1")3?'\Y^VG
M/^]L[3P5VSNO=E^^>O9<G+T7FYNO]V<R#\1H&J29S']]4N23S1=/U+=Q,)._
M/IDDZ2S(-\<REZ,\3.(G8I3$N8SAZ5Q&<CY-8OEKG#QY_</^SPST_C 9+T26
M+R)Z/<XWL_ _\I78WIKG>X*^F 2S,%J\$C_]523YWB"<R4R<R"O12V9!S%_N
MB7DP'H?QQ2NQ%<9BJ[4=QGMB5*19DKX209$G>SCG7$\T"]*+,(:'YY\$393+
M3_EF$(47\&4:7DSUW+<"!G""SWJKTN_]5^F5_VH*^J8I,IF&D\JT,-;P=>?3
M-!R&.7S1VM[_>?AZ_V=\"OZ:O_[AIJN*Y.0!+>JG>)C-]Y:LPP%[!+0CTSUW
MMLID>W9T6A-]O S2,(CS5S%29+2G4(,_PT+"V84((B!*PRKPS=;6=NO/^<43
MD:6C9;\P?%?A.)^^VGGQ8F\JD59>/7N*HY96\65AU@A;/D=IB@<XP[^+6(KM
MITV!PN5Q+^7Z&5:+JWH^U#,*-:6P'%WBYC^++ \G"X#D__[TSY?/?WFY]_\>
M'4*=]>CEV$F%_O_SI_ Z/1J"JH*W-W>?$TP]P-U^\?J/($UA4-'Y)--1F$G1
MODBEG,&3^S\7K_$)@?]XA-RY$C\PZ2 1?TR3F>CFXGVP$(=)/))I_.H;(/LZ
M2J_A!4408N<7 NXDN0P. !%G8*#,@I$L\G 41*"$NO&H)1KY5(J?_OEB9V=K
M#XCB,)G-@WB!I$%?;N]MB'DJ+\.DR**%"+.L !,IB,=B+*/P4J;P*4_$(BE$
MPX[R+HG ?'(&$4GJ3 )/K_K-?7'CE6AL;X@KIN9, P#&3%_.<SD;RA3%YDYY
M':5?%3=DWKH [GF1@MT&W*'6#7;9;);$L(/)Z&,3K*=47 91(<6/6ZVM;3&'
M\3) HW07>\BO]/$5=_P]T=C9 ##3$+:\O;E=MPC8FU5K,*_>!'X#!$R\:R8^
MJ)\8.0/FW%TRY\'GSXDTT7CJS+MSJWEOME=F7M$8)5&$5O6EC!9-X8]:-U0+
MK'MI)A%70,(:/I@A*U!HPFP@,_(  ,XDF,MACL 9 '"ID<S! A.!EJK 3V$\
MB@JTM@F*OGWQ3+]H9'!3C,G7,%JJC(_J*]X:OCFQ[0HN);=PFS1;AH#]2 (^
M2-HDDPF@'F4.(BT*9R'B,IG/P54KXC!?B#&@7NV#48!G0&()R"X8*DTNPS&\
M,H7-ASV&(:5^"N6/I8[2KARKJ2K*]=3.[9%MD(M @(PL1O"6F6.>AB,)JQ _
M[K2>;94GZ:G'+>#XN#ML$Q>A1YVDH.MP!""W%-!7,TWN$CSXJ*!>TGPJR,?E
M5Y.HF,4"74]$FX+E4 WH Z*E-N -@&W'L?PD#LBF #3F4]BI,FM4=$SMN#Z/
MGL^!P\G)08#">-G832*#:7 I^3NBCUGP$3Z*49!-+38 #_[>PMX@7/7H1A31
MSW%!\AG>)G1%"X2'=$"&7WJRZ#J$6EMLEA1QKC%I=R2Y-4[+%%F5>/;9$D>X
MJAAFPG'GS"I#">P9XP( ,/P>A18Q#1%5FA074_'BU=:6"%JS%HF##TGZ41PB
M"Z*(P/<\[Z8,=N?3/$P##(F((QC;A[H;8Y@DYI")N H!05DQFE:XCVG@*HPB
M8(J1#)$6"!C]8 /892PG8:Q,%\/_0QDE5]^/- 6:#2(C$581,9.Y)S<:56+K
MTPB>P"-.'$H9PV0789:3@>CJU4#]H'8]RV';B:!O+I=Z[@!]/<#?ETOUXU8Y
MJ?XYY!TE@L%0EJ"BR"A!@FN*@L29(XH\U+KXP1\ REFF^*Q)A-W4/RF%B !M
M_[*7B8]Q<A7)\04PP5 ZLQ*WP.;,X;-^U]]^?Q-;XC"8ASE0U']0AA( <9*+
M!!Y-KQ!HS4!*9P+U +_1=N-H,QF@H'#52\@RHVK)?!?\]D;ICZJP"B= $V"J
M+K=1FNY6 XXS1[<!UI.KE;;/<FMFM<8+8V#78*SIHUY+MT#"%R(8&;J#9]6P
MP3",5L\/'!+4@XQC2-0%TD I8P-*"3TMT1Z-DA1% IK\B O"#P^#* .5HUX9
ME^C<%6\EY$QR)766S\Q*!F/W80Q.(:P4F8Z?"8; 6PKV>MQI+<K<Y3&*!\IW
MP1\G28XR"N1_3+(=M@V$-/S#VN2L 6*0M.FBJ<6)O$3$FIVN6.)721&-P?0K
MF/J8&D?$/%/43#&(L5$81"*YBF6:3<,Y4R1)<T_+'=AG3\VSQ^993^UYF]E7
M%LM.0VY4S<Y&DK(,F,^C<,14 P0'ZZ'G9,1O-\7+ULN7_]KP90%+W236H1@V
MB*R-6B)V'9D!"8+<G1:CG-WP*_1, =G#!3ZPP?ADU*'47X:^6? IG!6SY1."
MX0CXR?GQ5!*S-5D9$?J#*(C9)ZE".D33,B+P@J%<T(-@)8<1 :)L-H(\!_,"
MP$26\M6B%49Z)L"V0#D3,N^A1MV 92QP-AN5&,'K44@O6#/SFOT'A_]J&L)S
MO"=#U)"@WM"ZE/,@5!A@J=+P0P/S8,$60RPF!>XG"QO?<4,O+[9.8]F*.N'U
MPZN&]!6'6$HS=FX,;XS'(8(-JRDYB!;^@DD1P$.RO%>[>!Q>BE$49-FO3\[>
M'OQ6RBF)[:VM?^E0YR:F[%2\4WU#J4GZ"M.9WEAO!KTG-0DTH3)HPIF@].YT
MLIDF5]4O1Q+0=?;VY/R]70,\@;E;]Z\?]J>IGOBL_;:S>=#KM'_;;+\9='JO
M0(U?!8ML3PQ!C\D40[RQ](#9$RJ))G;FG_;0$L:4[3^WZ#]X#U3P!3A@\7C3
M_ZF"@'=']0C@Q.<MES\X/3P.XX\K$6#P4!\0_]SDZ(JL#R[EH>BU-E@2L<MM
M\R#--8>#-LN (97K,)0H$*PSNO!$&08@2".0<))U8:<ZW1!$6:)T XI-/<A8
M9K &"<M' 8>2XBJA^/0@9=_J",C1L8$.HR3CK\'C=_UG=IE!-HD8\*C"MAW?
MA32!TBOM@/N.EN.;^V&MK!BB09"#S$4-Q_(,BR= />;!:*K<#Q2 F?7R#G&0
MIA<B+N8L):VB6N+MRK\*V"-X=G_X&ID RPCT;BW5<DIQ*.WJRF57U9MM^B[L
M.72,G7W-5N;;OO"B<[*B6)3^^F3KB4 9I2I?S.=L'HSTYSKEXJ7.MD#F/J'B
MH'_LYT:,7\J4<F=:[N3)G)["A\:E09\^\^#,QTN>VWY!S]&/MQ.493EY/>XX
MYT#(PVF7 Z<KA.X1./*PT#@#QY#%@.M?*0\J"S^!E09<#'\&<8QYR R<!,VX
MR)]DS%&\4GWI$&=EZ?!WBKL-?^,T:[I=T^VMZ);S$.3@(]FY ;\)1N4:SS;$
M0@9I1G8V4+%H/-]@.LYL(L?5O91779/KFESOCESCLD-H;"),3_[2>B#4]]4L
M&PQX8L0@&(WD/.=4 F>@D8E3.<&(#5M^-K5@0AX<[",=5)N^M)$!'H$FT4&2
MDMZ"[08G 0UYBMV@);[2MORFRYH^E-!%P9+K$\;*34)/+ _S(E<Q:A5.HDA<
MD4^3-/P/.VE8"@+/%K,9VA)U$7WMIP24U*4A=/(XN(!I+_#%$HL%F9_U)1AP
M8X.\2#% ="&UIP._PFA#"<_*BGIHB8,207 \/)5S<%1,I!1?NR:<Y3EYY8CT
M!@>^,31( 6\,",)CE-7R#"Z@V< &M);X7"I)ZY0N5%!*^..0J(ZY@Q.\L&QE
M(H3@/H]DAJ!GHS0<8H9WF%Q*SM2A[XW^J78:O;3%]2BIY+(HGDF.]-ADX"QO
M4J9/!22!8#WL+XE3.['5:X A7S]>%@SFN"O'+0VIU8!"#]AX-V9D<%/-CE:+
M8UJB;6(9NL!* T!,E9F*"\XQ*L)3\73D!A4%"/E1?(KK U6 $_QZDW/2 \=C
M_SDN2QBA:\_!6TZ+>CM*O,MY()T[N)1QJ>;%K;!H4W:X%%EHB3=%BJ';)@>&
M_?J#,K&7!70- IO.2C3&R/JCW;LIXH*L/L>PV]II!!NF&*-QL:'!JN9=2\%R
M@U:-=>UZI9+S8YJ]9[?!Q%</>MQ/H7FM:NI.7"L!LYZDICC&QUF>3W)4$#*=
M4MK%"C.AH@5*E3-*/'B/O325.0V_-"<'G&Q4:G/JHHF3$--3)I_9DYA+P3??
M8%#NQ>9OEAC.6_V66_2("^M\ A*,+[AD$ZB%]$RI\+-SZ&72QF$V4@J.^0,U
M.IJCUHX"! ")9<&(.86.4H%VH()*S7/6K,+PX7(#S(@:MUX(^$+RT:*,LSC
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MHCQUFIHH8V^Z*OA(=B ('93P-EBIA#FN4O7$H 8I*FM9.Y;3(24G.L^)3-C
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MS5=;;]HP%'Z?M/_@Y=TX 58)5%I5ZS8A=1>MK;2WRB0'L);8F>VLY=_OV+E
MVD ##].>L'.^[]Q\?(XYOWS*4O('M!%*SH)H$ 8$9*P2(5>SX/Z67MU^F,\#
M8BR7"4^5A%D@57!Y\?;-^3M*/X,$S2TD9+$A=^M")J"O50;DN]*6IX22,Q:-
MV3 <CDDTG([&T^$9^?Z%4L=_,LG4Q&O(.$$GI)D^+70J9L':VGS*V./CX\!]
M&2B]0@WAB GIW(@AJ/$F::$?1S4V8C^_W-QZW0TX%?)7%SR:3";,2VNHL;EN
MD-X% _%@I?XP)W'1C&KH"Z5MCYUXP4WC<6(UM9L<3#<'Q<R)G8F0AA$=1L%.
M;A+;]JHR\YZ5PL8(B&[O4=!R/E:%M'K3#:Z$+8(1\9Z\B+BMN= :RVB?ZDK:
MHL!3O.Z&.TD+*A>;5OYP/XA5YLLL/(O& >'6:K$H+'Q2.KN&)2]2S%TA?Q<\
M%4L!"59Y"AE(VP+LB"W7*[!?>08FYS$<ME=7L\ARK'LB.UG[:KF\ C<JYM;?
MP;T4MZ,UC[I/-!K2431 TP$[VH<)TRH%)F'E+G _/U*M6RSGQ<1Y$9WU]&+?
M=>JR;O;B_8JZU2G!=UZS?0Z\QO1[<TST+ZYMSPJH"2[I[T])]_;^]\IV#7>+
M8W)]H(WTLKM+J3<GV]]VIGX55L'=XO28V_VM7]"[G&9WL@L[/;.7^0;O5VVS
ME6$NI;)>1^T*SW,AE\IMW:";UM/N!RR)'ZA3KF/7+@Z/799KE8.V LSNP/0*
MUAJ6^.)8^$SX9ON0\L4 YT"->*&_W31]MT(*I#=;[VJNN[JSP&!*4R@S_ _C
M2&!Y;!Q($5*X(_C?@LDU'!L,4@P.8'Y<.(YZAR(B\.V'H]#Z*4X3%1=^@<]4
MBK_";JBK39UY_0%QO/L?\X-SO/2KO]+&J>VYE"^4/B_"BS ,\7U\7=G875[)
MA'STYLA\:^Z</;/5F"\,)-_DA5_'/(V+M$EJ1:H0781V3;V.?WYL+QBL=4[^
MR[-FP;K;2?4B(WQAK.8QOL>L+K#HW$GC43W4^<'TE-F9[QZP:XBSX!6,2+$5
MN-(L-9L"30E;..EGK8I\%OC_(%.!%8!O0%^"Y1=T"?\2S?&[BPJ+U'_%&R)4
M<N=Q2:%+,ZR)L6R]N/T+4$L#!!0    ( /M%SEBTG QGV00  .,L   4
M;F)Y+3(P,C0P-C$T7V1E9BYX;6S-6EUOXC@4?5]I_T,F^QS"1]O=HF%&B'9&
M:-LI*HQFM2\KDUS &L=&CE/@WZ\=/DJ'V#$4H[Q B$^NS[G^NCGBX^=E0KP7
MX"EFM.,W:G7? QJQ&--IQ_\^#+K#7K_O>ZE -$:$4>CXE/F?/_W^V\</0? 5
M*' D(/;&*V\TRV@,_(XEX T8%XAX@7<3-J["9KUYY36:[=95NWGC#1Z#0#U/
M,/W95A]CE((G>= T_]GQ9T+,VV&X6"QJRS$G-<:G,D:]%6[1_@:N6F.Q>V ?
M?!VN&W?0@]"+5HYMW-[>AGGK#IKB(J ,V@C_>7P81C-(4("I2DJDN*2XG>8W
M'UB$1)[)4@F>%J%^!5M8H&X%C6;0:M26:>SO$H=XQ!F!9YAXF\OOS_W#3& J
MPA@GX083(D(DX3S"C,-$2W2;/M7_M>KYC[TGQ6HNYT&*DSD!/WPOI9@E"-,@
M@60,_$1RA3'.3!,G0-4R"=:=G<I4$^:\9&<R&H^R,02[_D[D:XCD++\P01D1
M[T_PVS@:NENNOQ)5/='QJA:Q)-_ ZC=R)\N9RG4O0'8BY!!&67XA=\= ?F.Q
MDOO"A/$DWP;>*I#!@FV@G.G1<30*I$Y,L0(^R)\;K&+J0LN: RP%R,U^;S\B
M+#H8KW0[WBE$M2E["6/ JO^6NE"Y:*U'#/!_]WF'=V^6!$%C(!U?U[QF0M26
MR_A>.B['I'B&G9W1W69D^J^C,4)C @7LRJ"78RBG(O3EU$KM6![ '3%]@"DB
MZS'L+G$1.0W"<>9&,KPA4_O-CID,@&,6W]/X3NX,!DJ%.*=K\AFF.!4<4?$-
M)4743#"GS/JR9.9SQO.I/%1;:H]E5/!5C\5ZHE9/.>7]!1/XENW73 <D#R%.
M&8W0LA^KTV>"UZ5T";T2O%.NW3CFD*:;+[6#-;0\#=A+<.S)RR<^8@O]D:9%
M7H)?/ON?^("S%[Q^IS*2U, OP73 9,E$_L5SX](V@1VQ5 /7Y8 TO(J:79VQ
M,B 9S!C5[RTZB"-&/S@6LF#ML23)Z&:C*#K[C3A'W(:,X$A6[W3Z*"<UQX@4
M$-.#'+$:<%!9 +FZ\OI#5?O\:3(I',UR\&58]M,T WX45^TCKD8;HDQ.LE6C
M.1YA45C#ZR".&(TX4F[?<)6,6='4*VQWG)W[931#= J:.L\$<WH&W"? IS(9
M7SE;B)F<1W-$5]I#P(AVQ+,K)W6L)O87@J8%S K;G>:L)SOCB/3E"EO^#?IL
M:7 Z;J^F1Y=''N-R_7;\NGPJMX/:$6$IQ!U?\&PW-39.T^E6WX2SQ/R2R,KL
M"ME%F8C&V46\=2E.4E%L=6S57&)0#$;DJZ)2_X-9O.2_JCI-U^8FHP*6XI[D
MYTS'3V&J+H[6O>>[&W4>.BCL&$_H@A.SR*M_G[1#>\1"3K.R<@S6BH6N5N5T
ME?LR%K*N*BKK"!?'0N5U157J;" +23<5E61E'5GH^[.B^DHM)PMM?U5;F\ZL
MLE!V6VUE1H?+YJP^5RGL2)_!&;-15[U21.^OV>BI7BUB=NAL-%6O#K&P]VR$
M5:\2*;,';515K_*PM15MU%6O"#G.B+316+U"Q&QEVFBJ7@%B\$-M!%6O[BAW
M4VU>IJM:;UB8L#;RJE=P&)Q<&T'5JS@L;. ]OS'\19L,^_/3[K[Z4'^?E7?^
M!U!+ P04    " #[1<Y8=])SC?D%  !$/   %    &YB>2TR,#(T,#8Q-%]L
M86(N>&ULS5MA;^HV%/T^:?_!8U\VJ6D*[2JU:OM4M7U/:+1%A6K3GJ8I) :L
M);[(,2W\^]D.4 )V2"AV]J4$<G/.S;DGOG:27GV9)3%ZPRPE0*\;S>.3!L(T
MA(C0T77CM>?=]N[:[09*>4"C( :*KQL4&E]N?OSAZB?/^X8I9@''$1K,47\\
MI1%F]Y!@U 7&@QAYZ-QOGOFMD]89:K8N3\\N6^>H^^AY\OB8T'\OY9]!D&(D
M\J"I^GK=&',^N?3]]_?WX]F Q<? 1@+CY-1?1C<6X7)OQ%<'K ?_YF<[5Z%;
MT.^G*K9Y<7'AJ[VKT)3H @5HT__SL=,+QS@)/$*E**',)267J?JQ V' E9([
M3P$9(^0W;QGFR9^\9LL[;1[/TJBQ$HY!C%_P$,G/UY>VD?'"EQ$^Q2-9ITXP
MP+'(6$&,&1[JCXL9RQTFL[B0633/918_Z]#X?"+,D9)D$N.&_\D\NY@1B![H
M@1/6PUK(O,<#QFWDO@U\T.S[("[;P^:]#7G8C,78A0^<\1;D03-^P@=VQB;@
MH;+=(TV^G6*IW&(9TQ%;BS )5S"(*K;%D+T&BV<<BQ:T-DK&$&ZEGRX[18K#
MXQ&\^1$FLD6=R@U/;JC,Q9=_'B@G?"XZ6D#HDDJE>MTP[<XRB64C +9YAL40
M7KRN5"D)MJ5E.(4I"[,6*9AD'\?4>^TU;C(N]#UC^_O*_T@FG^8M6ZH6L'!'
M'HL(/P31"R<\?PY#!DF!5+!+@^R4!(42\D!%[8BK)LXX;V<DU=35$%&QM!LH
MMJNKZ-"RQI+1;85-HD$)-:S4^1[":8(I;],AL$3-R\0(@]L<)[JBEPFOZ( B
M2-MV6'*C-7+T7=(CQ>_6'*7$A:JJN;)-/QC$N)QE<J&?MXN"J\<JBKIVE^3U
M-#M$(Y15=_0%>($CUG?OZ0()X:KR1TBRU5+KG%*P2P*K-5VM#N_%K+J@N-JX
M/:N<PW)7[HQ6S!8B)(EKJ;Q>1BBMCQ4O9#.4%SPB*6<!Y4]!HK-"4=A>*X \
ME)N5P!'Z8$62MH85@4%"**N-11.T:0AL DSUEQX7_KN#*>5L?@>1V1.ECMK+
M(H7(KAR32^((J300,+1(!<E<:K!1.=5A3SDMFNPKB?'3-!E@9G34=LA>]OF
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M$:,_!9&0'@YY4:S9X4%1E0C4XAQQFW)*,B+AN^P1@EH01"N(F4&.6$T$5BK
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M$#-[G.U2IP[*V=S=VVIM+0SVBKZQIP:N7*# "@6?T3ZV%>DT$,#(@;5'A 5
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MV1S9PW#*J32;VSN[/QQ++OCTQ$2.+LG. G^VZZ7.]FZEWH)@L[E]/8/@7]+
M9Z"(8'-)51"(?08 %K'?  <I3Q)"LZWK0],%]C^GT;:I?R;"",P]"L=CJ7#'
MAJ'J,2U;SW,N)]7S:J_*NN.)'\Y$])C"D5=8=AI65[#4J.(K^%?[QAHY[Q?
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MZS$,V/3&).YXCV0?T\"MJD.=.?6J0_'2),W?E.E[F5U?8'H ZFURGYM(W2]
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M+BO3HTJLFS?NGN$O,!I8"BL#XH6/S+V?*DNNZ?%3H,L5X*^)^2!@)1!NPI_
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MJ/O=Q7GAN]&@$H57BU\B"&<Z3%\:O19B6?C#L'D4C_W._P-02P$"% ,4
M" #[1<Y8A4^<VG5&  #VDP$ #0              @ $     97A?-C@X,SDR
M+FAT;5!+ 0(4 Q0    ( /M%SE@MP.4'WBP  !01 0 -              "
M :!&  !E>%\V.#@S.3,N:'1M4$L! A0#%     @ ^T7.6 M@)9IF P  9PT
M !               ( !J7,  &YB>2TR,#(T,#8Q-"YX<V102P$"% ,4
M" #[1<Y8M)P,9]D$  #C+   %               @ $]=P  ;F)Y+3(P,C0P
M-C$T7V1E9BYX;6Q02P$"% ,4    " #[1<Y8=])SC?D%  !$/   %
M        @ %(?   ;F)Y+3(P,C0P-C$T7VQA8BYX;6Q02P$"% ,4    " #[
M1<Y8PNEZ]74$  ![+0  %               @ %S@@  ;F)Y+3(P,C0P-C$T
M7W!R92YX;6Q02P$"% ,4    " #[1<Y8)G97%_P8  "TE@  $@
M    @ $:AP  ;F)Y,C R-# V,31?.&LN:'1M4$L%!@     '  < N@$  $:@
$      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>nby20240614_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="nby-20240614.xsd" xlink:type="simple"/>
    <context id="d20248K">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001389545</identifier>
        </entity>
        <period>
            <startDate>2024-06-14</startDate>
            <endDate>2024-06-14</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="d20248K" id="ixv-345">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="d20248K" id="ixv-346">0001389545</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="d20248K" id="ixv-17">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="d20248K" id="ixv-356">2024-06-14</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="d20248K" id="ixv-357">NovaBay Pharmaceuticals, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="d20248K" id="ixv-358">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="d20248K" id="ixv-359">001-33678</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="d20248K" id="ixv-360">68-0454536</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="d20248K" id="ixv-361">2000 Powell Street, Suite 1150</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="d20248K" id="ixv-362">Emeryville</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="d20248K" id="ixv-363">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="d20248K" id="ixv-364">94608</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="d20248K" id="ixv-365">510</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="d20248K" id="ixv-366">899-8800</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="d20248K" id="ixv-367">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="d20248K" id="ixv-368">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="d20248K" id="ixv-369">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="d20248K" id="ixv-370">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="d20248K" id="ixv-371">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="d20248K" id="ixv-372">NBY</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="d20248K" id="ixv-373">NYSE</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="d20248K" id="ixv-374">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
